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Abstract
In polymer nanocomposites (PNCs), it is very important that the nanofiller
(typically an inorganic) is well-dispersed in an organic polymer matrix.

Optimal

compatibility results in end-use products such as packaging materials with enhanced
properties.

In practice, however, this is challenging to achieve because “ideal”

dispersions require the complete uniform separation, termed exfoliation, of the nanofiller
within the matrix. As a result, different nanofillers including calcium niobate (CN) and
montmorillonite (MMT) are first studied for their ability to exfoliate in aqueous
suspensions by measuring the organic cation uptake. The cation exchange capacity, or
CEC, determined that CN needs further work before introduction into a polymer matrix,
while MMT is more suitable for directly making PNCs. As hypothetical solutions, both
nanofillers are surface modified (after ion-exchange) and evaluated by characterization
testing.
To improve compatibility, the covalent grafting of phenylphosphonate (PPA) onto
exfoliated, protonated calcium niobate (HCN) was explored. PPA can be readily grafted
onto the face surfaces of exfoliated HCN, which has reactive apical oxygen atoms. HCN
can be fully exfoliated in aqueous solutions of tetrabutylammonium hydroxide
(TBAOH), denoted as TBACN. The effect of reflux conditions on the dispersion state of
TBACN suspensions was investigated, along with PPA grafting onto both non-exfoliated
HCN and exfoliated TBACN dispersed in deionized (DI) water, TBA solution, and

iv

various alcohols. The characterization results confirm the grafting of PPA on HCN and
TBACN, quantify the extent of PPA grafting, and identify various grafting modes
(mono-, bi-, and tridentate). All of these aspects are found to be dependent on the layered
materials’ exfoliation state, suspension processing conditions, and solvent composition.
The factors that control the dispersion of exfoliated MMT in poly(vinyl alcohol)
(PVOH) during solution blending and solvent evaporation were also studied in making
polymer nanocomposite films. Dynamic light scattering (DLS) indicates that addition of
dilute suspensions of fully exfoliated MMT platelets to aqueous PVOH solutions results
in undesired particle aggregation and thus poor MMT dispersion in cast films. It is
believed that PVOH bridging induces MMT platelet aggregation. To counteract bridging
aggregation, the novel idea of pretreating the MMT surface with a small amount of
compatible polymer prior to solution blending with PVOH was explored.

It is

hypothesized that “pretreating” the MMT platelet surfaces with adsorbed polymer in
dilute suspensions will protect the platelets from bridging aggregation during solution
blending and solvent evaporation. DLS shows that pretreated MMT platelets are less
susceptible to aggregation during blending with PVOH solutions.

Characterization

results compare the crystalline structure, thermal properties, dynamic mechanical
properties, gas permeability, and dissolution behavior of MMT/PVOH films
incorporating untreated versus pretreated MMT.
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Introduction
Polymer nanocomposites (PNCs) are extensively utilized in numerous products
and across a wide variety of industries.

In essence, the difference between a pure

polymer and a PNC as the choice of use for application is the addition of a suitable
nanofiller, an inorganic material consisting of stacked layers at the nanoscale, to the
polymer “matrix”. The purpose is to enhance the physical properties of the pure or
“neat” polymer that becomes a PNC with embedded nanofiller so as to improve
performance. This is achieved by creating an interfacial phase due to the nanofiller
dispersed within the “bulk” phase of the polymer. For optimal results, the nanofiller
layers need to be completely separated and dispersed uniformly throughout, called
exfoliation.

In practice, this is challenging because of the inorganic/organic

incompatibility between the phases that typically results in aggregation.
There are various techniques to make PNCs. Solution blending, melt extrusion,
and in situ polymerization are commonly employed among others. Solution blending is
the chosen route to make “model” or “ideal” PNCs, and therefore the focus for this work.
“Ideal” PNCs consist of nanofillers uniformly dispersed within the matrix resulting in the
direct enhancement of properties and performance. For this to happen, the polymer must
be able to strongly adsorb onto the surface of the filler nanoparticles. A common solvent
is also needed that both produces stable suspensions of exfoliated nanoparticles while
also solubilizes the polymer so that the two can be smoothly blended together. The
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selection of water calls for the studied nanofillers (montmorillonite and calcium niobatesee next paragraph) to be able to exfoliate in aqueous suspensions. On the other hand,
poly(vinyl alcohol) (PVOH) is a water-soluble polymer that is widely available that can
readily adsorb onto nanofillers including montmorillonite. It is also critical to control the
quality of the dispersion during solvent evaporation in forming the polymer
nanocomposite with the solution blending method. If these conditions are not met, PNCs
with sub-optimal properties may result.
To improve compatibility and to make more “ideal” PNCs, ion-exchange and
surface modification of nanofillers are two possible solutions. Calcium niobate (CN) – a
Dion-Jacobson synthetic perovskite – and montmorillonite (MMT), a naturally-occurring
silicate, are both platelet-shaped nanofillers studied in this work. In Chapter 1, the
organic cation uptake (or cation exchange capacity) of the nanoplatelets was measured as
an “indicator” for how well they may disperse in aqueous suspensions prior to adding to a
polymer.

Using these results proceeding forward, Chapter 2 describes the surface

modification of CN by covalently grafting phenylphosphonate as a first step towards
improving compatibility.

Lastly, Chapter 3 is devoted to determining the effect of

“pretreating” the surface of MMT with low-weight compatible polymers in PVOH
nanocomposites by characterization testing.
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Chapter 1: Organic Cation Uptake

1.1. Introduction
Chapter 1 discusses the measurement of the organic cation uptake of various
nanofillers including CN and MMT utilizing two methods: cation exchange and TGA.
For cation exchange, a copper ethylenediamine complex was mixed with a nanofiller and
measured for light absorbance; while TGA provided weight loss data for CN after cation
exchange.

The purpose of measuring the organic cation uptake is to evaluate a

nanofiller’s ability to uniformly disperse in aqueous suspensions. This provides a good
“indicator” of how well a particular nanofiller may disperse in a polymer matrix, or
whether the nanofiller may need further work before making a polymer nanocomposite
(PNC).

1.2. Copper Ethylenediamine Method
The cation exchange capacity (CEC) is a measure that can quantify the ability of a
nanomaterial to readily disperse in a suspension by exchanging cations. An established
protocol for measuring the CEC of clay minerals [1, 2] was adapted to explore the
organic cation uptake by protonated CN (HCN) and Na+ MMT (Cloisite Na+, Southern
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Clay Products). To start, 1.0 M solutions of copper (II) chloride dihydrate (Alfa Aesar)
and ethylenediamine (EDA, Alfa Aesar) are mixed in a 1:2 volume ratio, followed by
dilution with deionized (DI) water to produce a 0.1 M Cu(EDA)2+2 stock solution. The
stock solution is further diluted to make a series of standard solutions with concentrations
ranging between 0.002 M and 0.020 M. The solutions’ absorbances (at 548 nm and 800
nm) are measured by UV-vis spectrophotometry (model UV-2101PC, Shimadzu). The
absorbance at 800 nm is subtracted from that at 548 nm to correct for light scattered by
dust or residual particles in the solutions. This data is used to construct a calibration
curve giving [Cu+2] as a function of corrected absorbance at 548 nm.
For determining cation uptake by HCN, 0.1 g of inorganic powder was added to
10 mL aliquots of each of the standard solutions, mixed for 15 minutes, and centrifuged
(Eppendorf Centrifuge 5403, Brinkmann) at 6500 rpm for 30 minutes. The absorbances
of the supernatant solutions were measured by UV-vis spectrophotometry, again
subtracting the absorbance at 800 nm from that at 548 nm to correct for light scattered by
residual particles in the solutions. The calibration curve is used to determine [Cu+2]residual
in the solutions. For each solution, [Cu+2]initial-[Cu+2]residual gives the moles of Cu+2 per
liter exchanged into the inorganic powder. Using the solution volume (10 mL) and the
powder mass for each sample, [Cu+2]initial and [Cu+2]residual are converted to mEq per 100 g
of powder sample and plotted as [Cu+2]residual as a function of [Cu+2]initial (Figure 1.1). A
linear fit of the data points at higher [Cu+2]initial values intersects the x-axis at the CEC
value (0.405 meq/g).
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Utilizing this method (Figure 1.1), we also measured the cation uptake of 0.829
meq/g for Na+ MMT, in good agreement with literature values for cation exchange
capacity [2] and the manufacturer’s reported CEC value of 0.92 meq/g as measured by
ammonium acetate titration. The CEC for MMT is approximately twice that of HCN,
meaning that MMT can be dispersed more easily (after proton exchange with Na+) into
completely exfoliated dispersions in aqueous suspensions. This is because a higher CEC
value means that more cations in a nanofiller can be exchanged out for other cations more
facilely in a suspension that allows for the layered stacks to separate into individual
platelets. The physical separation of the negatively charged platelets can occur either by
electrostatic repulsion such as in water (MMT) or by introducing a bigger cation that gets
in between more compact nanosheets (CN) and forces the larger basal spacing. Figure
1.2 shows the stability of CEC values for various nanofillers including magadiite before
and after ion-exchange with time.
Nanofillers that are characterized to have higher CEC values tend to disperse
more completely and more uniformly in a suspension than those with lower values. This
means that an aqueous MMT suspension, for example, will provide a greater exposed
surface area that allows for the amplification of enhanced interfacial properties upon
addition into a polymer matrix than say an aqueous suspension of CN platelets.
Therefore, the properties of MMT in PNCs can be directly studied (Chapter 3), while
HCN requires further work (Chapter 2) beginning with introducing a bulky cation TBA+,
tetrabutylammonium, to achieve exfoliation via cation exchange. TGA can be used to
measure the organic uptake of TBA+ by HCN in the next section.
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Figure 1.1. Plot of residual Cu2+ concentration versus initial Cu2+ concentration
(expressed in units of mEq per 100 g of either HCN or MMT, as indicated) for
determination of cation uptake values. The x-axis intercepts of the linear fits (solid lines
based on three highest data points) give cation uptake values of 0.405 mEq/g and 0.829
mEq/g for HCN and MMT, respectively.
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Figure 1.2. CEC values of various nanofillers before and after ion-exchange with time.
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1.3. TBA+ Uptake of HCN as Measured by TGA
Samples for TGA were prepared from aqueous suspensions (HCN and 1:1 molar
TBA+:CN unit cells, henceforth TBACN) that were stirred for at least 7 days. After
centrifuging for 1 h at 6000 rpm, the recovered solid fraction was dried in an oven for 12
h at 50°C prior to TGA measurement. Figure 1.3 shows that the HCN sample lost 0.41%
of its mass upon heating to 150°C, presumably due to water loss. Between 150°C and
330°C, the remaining dry HCN (99.59% of the original sample) lost another 1.73% of its
mass due to a dehydration reaction producing calcium hexaniobate (Ca4Nb6O19), as
observed previously [3].
The TBACN sample lost a total of 8.67% of its mass when heated to 700°C
(Figure 1.3). The shape of the weight loss curve makes it difficult to resolve the distinct
contributions from water loss, TBA decomposition, and water elimination via the
dehydration reaction. To estimate the TBA weight loss, we assume that (1) the 1.16%
mass decrease up to 150°C is entirely due to water; (2) the dehydration reaction accounts
for 1.73% of the total mass loss up to 700°C; and (3) the residue at 700°C is Ca4Nb6O19.
Assumptions (1) and (2) imply that of the 8.67% total mass loss, 5.78% was due to TBA
decomposition.

Using 1.0 g of the starting TBACN solids as a basis, the TBA

decomposition accounted for 0.0578 g (0.239 mmol) and left 0.9133 g of Ca4Nb6O19
residue (0.894 mmol, corresponding to 1.788 mmol of HCN). The TBA:CN molar ratio
is thus estimated to be about 0.134. The results presented here are discussed further in
Chapter 2.
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Figure 1.3. Sample weight (expressed as a fraction of initial sample weight) versus
temperature for HCN and TBACN, as measured by TGA.

9

Chapter 2: Covalent Grafting of Phenylphosphonate on Calcium Niobate Platelets

Calcium niobate (CN) requires further study before introduction in a polymer
matrix based on the organic cation uptake results presented back in Chapter 1. In Chapter
2, a step is taken closer in that direction. After proceeding with cation exchange of
protonated calcium niobate with tetrabutylammonium in order to achieve full exfoliation,
the surface of CN is further modified by covalently grafting phenylphosphonate (PPA)
under various experimental conditions.

Several characterization techniques are then

employed to demonstrate grafting, which allows inorganic CN to now become
functionalized with organic groups that serve as the starting point for making tailored
polymer-grafted platelets. Thus, polymer nanocomposites (PNCs) may be composed of
compatible, exfoliated CN platelets.

2.1. Introduction
Inorganic platelets exfoliated in stable suspensions are potential building blocks
for making PNCs with enhanced properties and performance. In PNCs, the plateletpolymer interface (really an “interphase”) plays two crucial roles. First, the interphase
should promote platelet-polymer compatibility and thus platelet dispersion in the
polymer, maximizing interfacial area. Second, the interphase should have structure and
properties distinct from those of the bulk phases, as well as beneficial to performance in
end-use

applications.

Synergy

is
10

achieved

when

both

roles

are

fulfilled, because the interphase’s beneficial properties are amplified by the high
interfacial area/volume ratio achieved when the platelets are well dispersed.
Considerable research has focused on methods of adding organic functional
groups to the surface of inorganic platelets to improve polymer-platelet compatibility.
The classic example is ion exchange treatment of clay mineral platelets (e.g.,
montmorillonite) with alkyl ammonium cations to render them more hydrophobic.
Although this improves clay platelet compatibility with polymers, it does not (at least by
design) contribute significantly to improving composite functionality through beneficial
interphase structure or properties.
Covalent organic functionalization of platelet surfaces can be used to tailor the
interphase to enhance platelet compatibility with polymers and create “designer”
interphase structures.

Silane grafting chemistry is well established for layered

aluminosilicates (e.g., laponite [4-8] and montmorillonite [9-16]) via condensation
reactions with surface silanol or aluminol groups. Surface modification using
organophosphonic acids (oPAs) [17, 18], reviewed recently, offers enhanced hydrolytic
stability relative to silane grafting [17, 19]. Various oPAs have been used to chemically
modify ceramic membranes [20, 21], oxide particles [22-26], oxide thin films [27],
hydroxyapatite [28], and porous zeolites [29]. Grafting of oPAs onto the interlamellar
face surfaces of layered inorganics has been reported for kaolinite [30, 31], natural
phlogopite [32], hydrotalcite [33], layered silicates [34], and layered double hydroxides
[35-38]. Functionalization of polymers with oPAs [39] and polymers carrying oPA
functionality [40] have also been studied.
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This work explores the covalent surface functionalization of inorganic layered
perovskites [41-43] with oPAs. In the past, the surfaces of layered perovskites have been
modified via acid treatment [44] or other kinds of ion-exchange [45-50]. Several papers
describe various approaches for covalent surface modification of layered perovskites.
For example, n-alkoxy groups have been grafted to the interlayer surfaces of protonexchanged niobate [51-54], titanate [55], and tantalite [56] perovskites.

Alcohol-

functionalized niobates have been used as the starting point for subsequent grafting
reactions, such as interlayer polyether grafting [57].

Shimada et al. [58] first

functionalized the interlayer surfaces of HLaNb2O7xH2O with n-propanol, exchanged it
for n-decanol, and then proceeded with interlayer grafting using phenylphosphonic acid
(PPA) and n-alkylphosphonic acids. The work of Shimada et al. is the only report to date
of covalent functionalization of a layered perovskite with any oPA.
It is well known that layered perovskites may be exfoliated via cation exchange
with bulky alkylammonium cations in aqueous suspensions [41, 42, 59-67]. Much of this
work focused on calcium niobate, KCa2Nb3O10 (KCN), or its proton-exchanged form,
HCa2Nb3O101.5H2O (HCN). Using AFM with quantitative image analysis, Gao et al.
[67] proved that complete exfoliation of HCN in aqueous suspensions requires at least a
1:1 molar ratio of tetrabutylammonium cations (TBA+) to calcium niobate (CN) unit
cells. Use of lower TBA+ concentrations (or less bulky cations) result in incomplete CN
exfoliation. Steric interactions among bulky TBA+ cations limit the exchange of H+ for
TBA+ to about 15-20% of the theoretical cation exchange capacity. Thus the surface of
(TBA,H)CN (henceforth denoted as TBACN) has a significant number of Lewis acid
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sites (Nb-OH) available for reaction with oPAs.

No one to date has explored the

possibility of covalent surface modification of TBA-exfoliated CN by oPAs.
This work investigates the covalent grafting of PPA onto TBA-exfoliated CN
platelets. In particular, we explore the effect of solvent (water, aqueous TBA solution,
alcohols) on grafted amount and binding mode.

Dynamic light scattering (DLS)

characterizes the dispersion state of TBACN platelets in suspension.

31

P MAS NMR data

prove that PPA has grafted onto TBACN, and XRD results identify conditions for which
grafting occurs on platelet face surfaces, as opposed to edges and exterior particle
surfaces. XPS results provide estimates of the PPA grafted amount. Finally, FT-IR,
NMR, and XPS spectra provide evidence of different binding modes of PPA on CN
platelet surfaces.
Our investigation is timely and relevant for two reasons. First, CN and related
layered perovskite materials are well known as active photocatalysts with significant
potential for hydrogen production via water hydrolysis [68-78]. Recent work has shown
that TBA-exfoliated CN in water can be used to produce hydrogen gas [79-85]. Surface
modification of CN may be useful for maintaining its suspension stability and tailoring its
interfacial photocatalytic properties. However, CN’s photocatalytic activity may make it
difficult to covalently graft organic molecules onto its face surfaces, so this question
merits investigation. Second, prior studies of grafting onto layered perovskites (reviewed
earlier) all used organic solvents and examined interlayer reactions without consideration
of exfoliation. Compared to the multistep process of Shimada et al. [58], facile TBAmediated exfoliation of CN followed by grafting in aqueous suspensions may be a more
straightforward route to organically-modified CN and related perovskites.
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2.2. Materials and Methods
2.2.1. Materials
2.2.1.1. Exfoliated CN Suspension
Calcium niobate (KCa2Nb3O10, KCN) was synthesized as described previously
[67] and proton-exchanged in 6.5 M HNO3 to produce HCa2Nb3O101.5H2O (HCN).
Aqueous stock suspensions of TBACN were prepared following an established protocol
[67]. We add 1.0 g of HCN powder and 1.25 g of 40% w/w tetrabutylammonium
hydroxide (TBAOH, Sigma-Aldrich) solution to 150 mL deionized (DI) water, followed
by stirring at room temperature for a minimum of 7 days. The resulting suspension has a
1:1 molar ratio of TBA+ to HCN unit cells and contains, based on our previous work [67],
more than 95% exfoliated TBACN platelets.

2.2.1.2. PPA Grafting Protocol
In a typical grafting reaction, 25 mL of TBACN stock suspension was added to a
100 ml round-bottom flask and stirred, followed by addition of 0.27 g of
phenylphosphonic acid (PPA, Sigma-Aldrich, used as received); this quantity represents a
3:1 molar ratio of PPA to CN unit cells. The mixture was then refluxed at a temperature
near the solvent’s boiling point, with stirring and slow N2 bubbling, for 3 days. Reflux
reactions were usually carried out under lighted conditions in a fume hood. The flask
was located approximately 1 m below two standard, 32 W fluorescent bulbs (Phillips 700
series) behind a Plexiglas sheet. In some cases, reflux reactions were carried out in
darkness with the lights off and the flask/condenser wrapped in aluminum foil. The
products of grafting reactions prepared following this protocol are denoted as
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PPA+TBACN(light) and PPA+TBACN(dark), with the terms in parentheses denoting
variations in suspension and/or reflux conditions.
For TBACN, suspension conditions prior to PPA addition were also varied,
including (1) additional dilution, or (2) drying followed by re-dispersion in a new solvent.
For dilution cases, 25 mL of TBACN stock suspension was diluted with 25 mL of either
DI water or TBAOH solution; these suspensions are denoted as TBACN(dil-DI) and
TBACN(dil-TBA), respectively.
Experiments were also carried out in which 25 mL of the TBACN stock
suspension was dried and then re-dispersed in 50 mL of a new solvent (DI water;
TBAOH solution; 94-96% anhydrous, denatured ethanol, Alfa-Aesar; 99.5+% ethanol,
Sigma-Aldrich; 99.5+% n-propanol, Alfa-Aesar; or n-propanol diluted with water to 95%
n-propanol). The stock suspension was dried in the flask by heating in an oven at 90100°C. After adding 50 mL of the new solvent, the suspension was ultrasonicated for 10
min (Solid-State/Ultrasonic FS-28, Fisher Scientific) and stirred for at least 1 h at room
temperature. These suspensions are denoted, for example, as TBACN(dried, dil-DI) for
the case of re-dispersion into DI water. The product of the grafting reaction for this
suspension is denoted as PPA+TBACN(dried, dil-DI), with corresponding notation used
for other solvents.
For reactions utilizing non-exfoliated HCN without TBA+, the corresponding dry
weight of HCN powder (0.30 g) was weighed into the flask, followed by addition of 50
mL of solvent (DI water, alcohols). The suspension was sonicated for 10 min and then
stirred at room temperature for at least 1 h. Products of grafting reactions are denoted,
for example as PPA+HCN(dil-DI).
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After cooling to room temperature, the suspension was centrifuged at 6000 rpm
for 1 h to recover the product. All products were washed twice with DI water (with
mixing, sonication, and centrifugation) to remove unreacted PPA. The final products
were dried overnight in an oven at 90-100°C.

2.2.2. Characterization Methods
Powder X-ray Diffraction (XRD) patterns were acquired using an X-ray
diffractometer (Rigaku Ultima IV, Cu Kα radiation, λ = 1.5418 Å), typically over the 2θ
range of 2-20º with a step size of 0.04º and a scan speed of 0.25º/min.
31

P MAS NMR Spectroscopy. Solid-state

31

P MAS NMR spectra were collected

on either a Varian Inova 500 MHz or a Bruker Avance III-HD 500 MHz spectrometer
(202.49 MHz). The Varian spectrometer used a Doty Scientific 4mm XC MAS probe.
These spectra were collected at ambient temperature with a sample rotation rate of 10
kHz and TPPM decoupling at a 1H field strength of 64 kHz. The Bruker system was
fitted with a 1.9 mm MAS probe. These spectra were collected at ambient temperature
with a sample rotation rate of 20 kHz.

1

H dipolar decoupling was performed with

SPINAL64 modulation and 145 kHz field strength. Bloch decays were collected with 50
ms acquisition time over 300 or 400 ppm spectrum width with a relaxation delay of 10 s.
Chemical shifts are reported with respect to H3PO4 and referenced externally with NH4・
H2PO4, which was assigned a value of 0.72 ppm.
Fourier Transform-Infrared (FT-IR) spectra were obtained utilizing a PerkinElmer Spectrum 100 FT-IR Spectrometer.
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X-ray Photoelectron Spectroscopy (XPS) measurements utilized a Kratos AXIS
Ultra DLD XPS system equipped with a monochromatic Al Ksource. The energy scale
of the system is calibrated using an Au foil with Au4f scanned for the Al radiation and a
Cu foil with Cu2p scanned for the Mg radiation resulting in a difference of 1081.70 
0.025 eV between these two peaks. The binding energy is calibrated using an Ag foil
with Ag3d5/2 set at 368.21  0.025 eV for the monochromatic Al X-ray source. The
monochromatic Al Ksource was operated at 15 keV and 120 W. The pass energy was
typically fixed at 40 eV for the detailed scans.

A charge neutralizer was used to

compensate for the surface charge.
Thermogravimetric Analysis (TGA) (TA Instruments, model Q5000-0413)
quantified the temperature-dependent mass loss of dried CN samples. Samples were
placed on a Pt pan and heated in air from room temperature to 700°C with a 10°C/min
ramp rate.
Dynamic Light Scattering (DLS) measurements employed a Zetasizer Nano ZS
(ZEN3600, Malvern Instruments). Every DLS measurement was accompanied by a
calibration test using 0.24 μm polystyrene latex microspheres (Bangs Laboratories, Inc.)
as a sizing standard. Samples for DLS were diluted with specified solvent to a consistent
concentration (~5 x 10-5 g/mL, ~1 mL sample volume), sonicated for at least 10 minutes,
mixed on a vortex mixer, and then characterized at 25°C. DLS theory for platelet-like
particles is not well developed [86]. We use the quadratic cumulant method with the
Stokes-Einstein equation to determine the effective spherical diameter of CN particles in
suspension.
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2.3. Results and Discussion
2.3.1. Characterization of HCN and TBACN
2.3.1.1. As-Prepared HCN and TBACN
Proton-exchanged CN (HCN) and TBA-exfoliated CN (TBACN) have physical
characteristics similar to those previously reported [67].

Upon heating from room

temperature to 150°C, HCN loses about 0.4% of its mass due to loss of residual moisture
in the sample (Figure 2.1a). From 150°C to 700°C, HCN undergoes an additional 2.2%
mass loss. Most of this loss (1.9%) occurs between 250°C and 350°C and is due to a
dehydroxylation reaction producing calcium hexaniobate (Ca4Nb6O19), as observed
previously [87]. The (001) peak in the XRD pattern for HCN (Figure 2.1b) is located at
2θ = 6.05°, giving a d-spacing of 1.46 nm; the full pattern has been published previously
[67].
After exfoliation with TBA+ (1:1 TBA:CN molar ratio), the resulting TBACN
forms a stable suspension of exfoliated platelets [67]. DLS measurements (Table 2.1)
indicate an equivalent spherical diameter of 390 nm for TBACN particles in stock
suspension, comparable to the 451 nm size reported previously [67]. Dilution of stock
suspension into DI water, stirring for three days, and then further dilution with DI water
does not lead to aggregation, since the particle diameter (365 nm) remains about that of
the original suspension. After drying the stock suspension, TBACN particles readily redisperse in aqueous TBA solution (D = 328 nm), but not in DI water (D = 650 nm).
TGA analysis of dried TBACN indicates a mass loss of 2.5% up to 150°C
(assumed to be residual moisture), and a further loss of 11.6% from 150°C to 700°C. The
peak rates of mass loss, around 250°C and 325°C, are associated with TBA+
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decomposition.

After accounting for an estimated mass loss of 1.6% due to the

dehydration reaction, the remaining TBA+ mass loss leads to a 0.21 molar ratio of TBA+
to CN unit cells. Repeated measurements give an average TBA:CN ratio of 0.18±0.03,
consistent with previous reports [61]. XRD analysis of dried TBACN powder gives the
expected XRD pattern [67] with the broad (001) peak indicating a d-spacing of 2.48 nm,
consistent with turbostratic ordering of restacked TBA-coated CN platelets. The small
secondary peak at 6° probably represents some non-exfoliated HCN.
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Table 2.1. DLS results for TBACN suspensions (aqueous and alcoholic).
suspension concentrations were 5.0×10-5 g/mL for all DLS measurements.

Sample ID

The

Description

DLS
Diluent
(a)

Sphere
Diam.
(b)
(nm)

Platelet
Length
(c) (nm)

As-prepared stock suspension, TBA+HCN
TBACN diluted 1:1 (v/v) in DI, stirred for 3
days
TBACN dried, then re-dispersed in DI water
TBACN dried, then re-dispersed in TBA
solution

TBA/DI
DI

390
365

540
488

DI
TBA/DI

650
328

1159
416

dil-

TBACN diluted into 95% ethanol for DLS
TBACN dried, re-dispersed into 95% ethanol

Et95
Et95

352
474

462
723

dil-

TBACN dried, re-dispersed into 99% ethanol

Et99

897

1881

dil-

TBACN dried, re-dispersed into 95% npropanol
TBACN dried, re-dispersed into 99% npropanol

nPr95

509

805

nPr99

459

689

Refluxed suspensions
TBACN(dil-DI,
reflux)
TBACN(reflux)

TBACN diluted 1:1 in DI, refluxed 3 days in
light
TBACN refluxed 3 days in darkness

DI

398

556

TBA/DI

400

560

PPA-grafted
suspension
PPA+TBACN

TBACN + 3:1 (molar) PPA, refluxed in light

TBA/DI

392

544

As-prepared
suspensions
TBACN
TBACN(dil-DI)
TBACN(dried, dil-DI)
TBACN(dried,
dilTBA)
TBACN(dil-Et95)
TBACN(dried,
Et95)
TBACN(dried,
Et99)
TBACN(dried,
nPr95)
TBACN(dried,
nPr99)

dil-

(a) Solvent used to dilute sample for DLS; abbreviations: DI = deionized water; TBA/DI = aqueous TBA
solution; Et95 = 95% ethanol (balance water); Et99 = 99% ethanol (balance water); nPr95 = 95% npropanol (balance water); nPr99 = 99% n-propanol (balance water).
(b) Intensity-mean equivalent spherical diameter.
(c) Average platelet length based on Eqn. (3) in ref. [86].
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Figure 2.1. Characterization of as-prepared HCN (solid curves) and TBACN (dashed
curves): (a) mass (%) and its derivative as functions of temperature from TGA, and (b)
XRD patterns over the low-angle range. Numbers in (a) indicate “total” (non-water)
percentage mass decreases from 150°C to 700°C.

21

2.3.1.2. Effect of Suspension Processing and Reflux Conditions on TBACN
TBACN suspensions were refluxed in darkness and under fluorescent lights as
control experiments for the PPA grafting experiments discussed in section 2.3.2. For
TBACN refluxed in darkness, the dried product exhibits a 9.1% mass loss from 150°C to
700°C (Figure 2.2a), slightly less than that found for the starting stock suspension. The
derivative mass loss pattern is also similar to that of the starting TBACN stock
suspension (Figure 2.1a).

Most of the mass loss occurs between 150 and 350°C,

presumably due to TBA+ oxidation and fragmentation. Additional mass loss up to 550°C
probably occurs due to oxidation of the residual carbonaceous char (see Figure 2.1a).
XRD results (Figure 2.2b) show that TBACN refluxed in darkness has a d-spacing of
2.66 nm, close to that of starting TBACN (2.48 nm). These results indicate that refluxing
TBACN in darkness does not have much of an effect on the state of the TBACN
platelets.
In contrast, the product of refluxing TBACN suspension in the light exhibits a
5.2% mass loss between 150°C and 700°C (Figure 2.2a), less than half that of the starting
stock suspension.

The derivative mass loss pattern differs from that of the stock

suspension as well; the peak rate of mass loss occurs at 250°C. The d-spacing of
TBACN refluxed in light decreases from 2.48 nm to 1.52 nm (Figure 2.2b). These results
indicate that HCN may catalyze the degradation of TBA+ in the presence of light at
elevated temperatures.

This should not be surprising, given the well-established

photocatalytic properties of HCN and other layered perovskites [68-85].
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Figure 2.2. Characterization of TBACN refluxed in light (solid red curves, “light”) and
in darkness (solid black curves, “dark”): (a) mass (%) and its derivative as functions of
temperature from TGA, and (b) XRD patterns over the low-angle range. Panel (b) also
includes patterns for as-prepared HCN (dotted black curve) and TBACN stock
suspension (dashed red curve). Numbers in (a) indicate “total” (non-water) percentage
mass decreases from 150°C to 700°C.
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TGA and XRD provide useful information on the effect of sample processing
conditions on the state of TBACN. Figure 2.3 summarizes TGA mass loss results for
TBACN suspensions subjected to various processing conditions and refluxed under
lighted conditions. As-prepared HCN does not contain TBA+, so it exhibits only a small
mass loss due to dehydroxylation. For TBACN diluted 1:1 (v/v) with DI water, stirred,
but not refluxed (Figure 2.3, “TBACN(dil-DI, stir)”), the mass loss values over 150350°C and 150-700°C are about 15% less than those of the TBACN stock suspension.
This suggests that dilution into DI water may result in desorption of some weakly bound
TBA+ from the HCN platelets.
The last three samples in Figure 2.3 are TBACN stock suspensions diluted and
refluxed under lighted conditions. The mass loss values for TBACN diluted 1:1 into DI
water and refluxed [TBACN(dil-DI, reflux)] are 30% lower than those for TBACN stock
suspension.

This might be explained by a combination of TBA+ desorption and

photocatalytic-degradation. The mass loss values are even lower if TBACN is dried
before re-dispersion into DI water and refluxed [TBACN(dried, dil-DI, reflux)]. DLS
results (Table 2.1) indicate that after drying, TBACN platelets do not fully re-disperse in
DI water. While not necessarily favoring TBA+ desorption, the local environment in
TBACN aggregates may be more favorable for photo-degradation. Finally, TBACN
diluted 1:1 into TBA solution and refluxed [TBACN(dil-TBA, reflux)] has the lowest
mass loss values (about 60% less than TBACN stock suspension). This sample thus had
the lowest final TBA content, despite the excess TBA+ initially present. This may be
explained by active TBA+ photo-degradation catalyzed by HCN.
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Figure 2.3. Fractional mass losses measured by TGA for as-prepared HCN and TBACN
subjected to various processing conditions: as-prepared stock suspension (TBACN);
TBACN diluted 1:1 with DI water and stirred [TBACN(dil-DI, stir)]; TBACN diluted 1:1
with DI water and refluxed [TBACN(dil-DI, reflux)]; TBACN dried, re-dispersed in DI
water, and refluxed [TBACN(dried, dil-DI, reflux)]; and TBACN diluted 1:1 with TBA
solution and refluxed [TBACN(dil-TBA, reflux)]. The starting suspensions all had the
same TBACN wt%, and were refluxed in light. Numbers above each pair of bars denote
the total fractional mass loss from 150 to 700°C. Trend lines are drawn to guide the eye.
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XRD characterization (Figure 2.4) generally supports the TGA analysis. TBACN
suspension diluted 1:1 in DI water and only stirred [TBACN(dil-DI, stir)] has an XRD
pattern (after drying) like that of undiluted TBACN suspension (Figure 2.1b). The (001)
peak gives a d-spacing of 2.57 nm, consistent with restacking of TBA-covered CN
platelets. A small peak at 1.52 nm indicates the presence of some non-exfoliated HCN.
TBACN suspension diluted 1:1 in DI water and refluxed [TBACN(dil-DI, reflux)] has a
similar XRD pattern (primary d-spacing of 2.66 nm), but with a larger secondary peak
near 6° (1.48 nm). In this case, desorption and/or degradation of some TBA may have
caused restacking of some HCN platelets with less (or no) TBA+ in the interlayer spaces.
For the TBACN suspension that was first dried, re-dispersed in DI water, and refluxed
[TBACN(dried, dil-DI, reflux)], the XRD pattern does not show strong Bragg reflections,
indicating disorder in the dried product. Magnification shows that there is a peak near
5.8° (d-spacing 1.55 nm) that could be some non-exfoliated or restacked, bare HCN. The
main observation is the near absence of a (001) peak near 3.4° associated with restacked,
TBA-coated CN platelets, consistent with desorption and photo-degradation of the TBA+.
Lastly, the pattern for TBACN suspension diluted 1:1 in TBA solution and refluxed
[TBACN(dil-TBA, reflux)] also has no 3.4° (001) peak, but it does have a prominent
peak near 6° (1.48 nm). This is consistent with considerable photo-degradation of the
TBA+, followed by platelet restacking during the drying of the product.
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Figure 2.4. XRD patterns of TBACN subjected to various processing conditions:
TBACN diluted 1:1 with DI water and stirred [TBACN(dil-DI, stir)]; TBACN diluted 1:1
with DI water and refluxed [TBACN(dil-DI, reflux)]; TBACN dried, re-dispersed in DI
water, and refluxed [TBACN(dried, dil-DI, reflux)]; and TBACN diluted 1:1 with TBA
solution and refluxed [TBACN(dil-TBA, reflux)]. The starting suspensions all had the
same TBACN wt% and were refluxed in light.
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2.3.2. PPA Grafting in HCN and TBACN Aqueous Suspensions
2.3.2.1. Evidence for PPA Grafting and Grafted Amounts
We now consider covalent modification of HCN and TBACN using
phenylphosphonic acid (PPA). As in previous studies of organophosphonic acid grafting
[22-24, 29, 32, 36, 58, 88, 89], 31P MAS NMR (Figure 2.5) provides direct evidence for
PPA grafting onto calcium niobate. The NMR spectrum for pure PPA (Figure 2.5a) has a
signature peak at 21.4 ppm. The other spectra in Figure 2.5 are for the washed, dried
products of refluxed HCN or TBACN suspensions with added PPA. In all cases, the
spectra show broad, sometimes multimodal peaks shifted 4-17 ppm upfield relative to the
peak for pure PPA. The peak locations for the reflux products (centered at around 11-13
ppm) are consistent with previous reports for PPA grafting onto titania [23] and layered
lanthanum hexaniobate [58]. None of the product spectra in Figure 2.5 have peaks at
21.4 ppm indicative of free, non-grafted PPA. These spectra show that PPA readily
grafts onto HCN and TBACN platelets. The apparent presence of multiple, overlapping
peaks suggests different PPA grafting modes, which will be discussed in section 2.3.2.4.
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Figure 2.5. 31P MAS NMR spectra with peak fitting for: (a) pure PPA, (b) PPA+HCN
refluxed in DI water and in light, (c) PPA+TBACN refluxed in light, and (d)
PPA+TBACN refluxed in darkness. PPA was added to CN in a 3:1 molar ratio.

XRD patterns for the washed, dried products (Figure 2.6) provide evidence about
the location of PPA grafting. The pattern for PPA refluxed in DI water with nonexfoliated HCN has one peak at 6.05° (d-spacing 1.46 nm), essentially the same as that of
the as-prepared HCN (Figure 2.1b). This shows that PPA does not penetrate HCN’s
interlayer space, but instead grafts solely on the exterior of the non-exfoliated HCN
particles. The patterns for PPA added to TBACN suspension and refluxed (in light or in
darkness) have distinct, broad peaks centered near 4.2° with d-spacings in the 2.1-2.2 nm
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range, in between the d-spacings of as-prepared HCN (1.46 nm) and TBACN stock
suspension (2.48 nm). These patterns also have smaller peaks at 5.84° (1.51 nm), but no
evidence of a peak at 3.56° (2.48 nm) consistent with the starting TBACN; this shows
that PPA grafting at least partially displaces adsorbed TBA+.
Taken together, the NMR and XRD data show that PPA has been grafted onto the
face surfaces of the exfoliated TBACN platelets. Upon drying, these “PPA+TBACN”
platelets restack with turbostratic order with an average interlayer gap width expanded by
about 0.7 nm relative to HCN (for PPA+TBACN prepared in the light, 2.17 - 1.46 nm =
0.71 nm).

This expansion is consistent with that reported previously for interlayer

grafting of PPA on layered double hydroxides [36, 38], interpreted in terms of a bilayer
of grafted PPA molecules with tilted orientation. Alternately, the 0.71 nm expansion
approximately equals the length of a PPA molecule [37, 58, 90-93], possibly consistent
with an “interdigitated” bilayer of grafted PPA molecules oriented normal to the surface
[32]. Although these pictures of the interlayer structure are speculative, the NMR and
XRD data provide clear evidence that PPA has been grafted onto the face surfaces of the
exfoliated TBACN platelets. We are not aware of any previous reports of covalent
grafting onto any kind of exfoliated niobate platelets.
Previous studies suggest the possibility of side reactions between PPA and
TBACN to form small quantities of layered calcium or niobium phenylphosphonate
(CaPPA, NbPPA). Reports of the synthesis of layered CaPPA [94, 95] provide XRD
patterns and 31P NMR spectra. The XRD pattern for CaPPA [95] has three distinct peaks
(at about 5.7°, 11.5°, and 17.4°) that are difficult to distinguish from those of residual
unexfoliated HCN. The 31P NMR spectrum of hydrated CaPPA [95] has two peaks: one
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at 20.0 ppm is not seen in the product spectra in Figure 2.5, and the other at 12.4 ppm
overlaps with those seen in Figure 2.5. Thus the quantity of CaPPA produced in the
grafting reactions carried out in this work is likely to be small or nonexistent. The
synthesis of NbPPA has not been reported in the literature. We have recently synthesized
NbPPA via a melt process, to be reported in a future publication. The peaks in the XRD
pattern attributable to NbPPA do not match the peaks in XRD patterns for our products,
so we can rule out the presence of NbPPA as a byproduct.

Figure 2.6. XRD patterns for: TBACN; PPA+HCN refluxed in DI water and in light;
PPA+TBACN refluxed in light; and PPA+TBACN refluxed in darkness.
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The XRD patterns in Figure 2.6 imply that PPA grafting removes at least some of
the adsorbed TBA+ from the surfaces of the PPA+TBACN products, as evidenced by the
absence of peaks at 3.56°. TBA+ could be eliminated by photocatalytic-degradation or
physical displacement from the HCN surface by grafted PPA. FT-IR spectra (Figure 2.7)
provide additional insight. The FT-IR spectrum for TBACN shows strong bands at 2961,
2933, and 2874 cm-1 associated with CH3 stretching and symmetric and asymmetric CH2
stretching vibrations, respectively [96-98]. However, these bands are much weaker in the
PPA+TBACN products. The same is true for CH3 and CH2 bending vibrations in the
1500-1370 cm-1 region (see section 2.3.2.4) [96, 98]. These observations indicate that the
amounts of residual TBA+ in the PPA+TBACN products are relatively small.

Figure 2.7. FT-IR spectra in the 3500-2500 cm-1 range for: TBACN; PPA+TBACN
refluxed in light; and PPA+TBACN refluxed in darkness.
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The TGA mass loss and derivative mass loss curves (Figure 2.8) also provide
additional information. The mass loss curves (Figure 2.8a) appear to be shifted vertically
relative to each other, mainly due to differences in water loss below 150°C. Between 150
and 350°C, the PPA+HCN product loses 2.0 wt%, almost equal to that of as-prepared
HCN (1.8 wt%, Figure 2.1a); the peaks in the derivative mass loss (i.e., mass loss rate,
Figures 2.1a and 2.8b) are similar, as well. This implies that the 150-350°C mass loss for
PPA+HCN is due to CN dehydroxylation. The PPA+HCN product loses 4.2 wt% from
350 to 550°C (Figure 2.8a) and has a distinct peak in the mass loss rate curve at 500°C
(Figure 2.8b). As-prepared HCN loses almost no mass (0.2 wt%, Figure 2.3) over the
same temperature range.

From this, we infer that the decomposition of PPA in

PPA+HCN occurs only in the 350-550°C temperature range, consistent with previous
reports for PPA decomposition after grafting onto other metal oxides [24, 37].
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Figure 2.8. TGA characterization of mass percentage (a) and its derivative (b) as
functions of temperature for:
PPA+HCN refluxed in DI water and in light;
PPA+TBACN refluxed in light; and PPA+TBACN refluxed in darkness. Numbers in (a)
indicate percentage mass decreases from 350°C to 550°C.
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The derivative mass loss patterns for the PPA+TBACN products in the 150350°C range (Figure 2.8b) are similar to that of TBACN suspension refluxed in light
(Figure 2.2a). Presumably, these mass losses are associated with residual TBA+. The
PPA+TBACN products lose significant additional mass in the 350-550°C range (Figure
2.8a) with distinct acceleration between 425 and 500°C (Figure 2.8b), again consistent
with PPA decomposition in oxidizing environments [24, 37]. Figure 2.9 quantifies the
TGA mass losses over the key temperature ranges. Both of the PPA+TBACN(light,
dark) products have significantly larger losses in the 350-550°C range than the
corresponding refluxed TBACN stock suspensions (Figure 2.9). The additional mass
losses must be due to the decomposition of grafted PPA.
For refluxed TBACN suspensions (Figure 2.9), most of the mass loss occurs over
150-350°C, but TBA+ decomposition continues through the 350-550°C range. Thus, we
cannot assume that the 350-550°C mass losses are entirely due to PPA decomposition for
the PPA+TBACN products.
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Figure 2.9. Fractional TGA mass losses for various products after refluxing (in darkness
or in light, as indicated in the category label): as-prepared TBACN stock suspension
(TBACN); PPA added to aqueous, non-exfoliated HCN (PPA+HCN); and PPA added to
TBACN stock suspension (PPA+TBACN). The number above each bar denotes its
percentage of the total fractional mass loss from 150 to 700°C.

TGA-based estimates of PPA grafted amounts are also complicated by uncertainty
in the stoichiometry of PPA oxidation during TGA.
PPA+TBACN refluxed in light,

For the TGA residue from
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P MAS NMR and FT-IR results (Figures 2.10 and

2.11) indicate the presence of free (PO4)3- and (HPO4)2-, perhaps as Ca3(PO4)2 and
CaHPO4. Thus, during TGA in air, PPA loses its phenyl ring but gains oxygen atoms as
it is oxidized to phosphates, which may have complex stoichiometry [99, 100]. This
makes it difficult to estimate the moles of PPA from the net mass loss without additional
data or making strong assumptions.
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Figure 2.10. 31P MAS NMR spectrum for PPA+TBACN, refluxed in DI water and in
light, and then heated at 700°C in air for 12 h. Deconvolution gives a sharp primary peak
at 2.74 ppm, and a weaker, broad secondary peak centered at 1.22 ppm. The primary
peak agrees with that of Ca3(PO4)2, as reported previously [101]. The secondary peak
may represent protonated phosphate [102], perhaps as CaHPO4.
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Figure 2.11. FT-IR spectrum for PPA+TBACN, refluxed in DI water and in light, and
then heated at 700°C in air for 12 h (“PPA-HCN decomp.”). The figure also shows the
spectrum for the starting material, protonated calcium niobate (HCN). Peak assignments
for HCN: peak (1) at 1635 cm-1 is H-O-H bending; and the peak/shoulder (2) at 942 and
904 cm-1 are Nb-Oterminal stretching vibrations [103]. Peak assignments for PPA-HCN
decomp.: peaks (3) centered at 1046 and 1096 cm-1 are vibrations of PO43-; peak (4) may
be HPO42- [99, 100]; peak (5) is as yet unidentified; speculating, it could be a Nb-O-P
vibration.

PPA grafted amounts can be estimated from XPS results (Table 2.2). For asprepared HCN and TBACN stock suspension, the O:Nb ratios are close to the expected
value of 3.33 (10:3). The Nb:Ca ratios for HCN (2.73) and TBACN (1.75) are higher
than the expected value of 1.5, perhaps due to shielding of the Ca atoms within the CN
structure.
XPS also provides the molar percentage of P atoms in samples with added PPA;
each HCN unit cell contains 3 Nb atoms, so 3(P:Nb) gives the PPA:CN molar ratio. The
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maximum possible PPA:CN ratio is 2, assuming one reactive apical oxygen on each face
surface of the CN unit cell and monodentate PPA grafting. The maximum “practical”
ratio may be less than 2 due to steric hindrance, since the reported 0.24 nm2 parking area
for a phosphonate graft [20, 22, 23, 58, 104] is greater than the 0.148 nm2 area of one CN
unit cell [105]. Based solely on steric considerations, the maximum PPA:CN ratio may
be as little as 1.23 (=2×0.148/0.24). PPA grafting via bi- or tridentate binding modes
(discussed below in section 2.3.2.4) might further reduce the PPA:CN ratio.
For PPA+TBACN suspensions refluxed in light or in darkness, the measured
PPA:CN ratios are both just over 0.5 (Table 2.2). This represents a graft density of about
1.70/nm2 [=0.5/(2×0.148)], which is less than the 4.8/nm2 reported for PPA grafting on
TiO2 [23]. In addition to the factors mentioned above, PPA must displace adsorbed
TBA+ in order to graft onto the CN surface, which probably hinders grafting. PPA’s
acidic protons probably assist by exchanging for TBA+, but ion exchange, and thus
displacement, do not appear to be complete. For PPA grafted onto unexfoliated HCN
particles, XPS yields a higher PPA:CN ratio, 0.785, equivalent to a graft density of
2.65/nm2. In this case, PPA does not compete with TBA+ for space on the surface. The
PPA:CN ratio may be underestimated in this sample because PPA grafts only on the
exterior surface of the HCN particles, while the XPS X-rays may penetrate multiple CN
layers.
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Table 2.2. XPS results for elemental compositions and PPA:CN ratios of PPA+CN
products.

Sample ID
HCN (HCa2Nb3O101.5H2O)
TBACN

Composition (mol%)
P
Ca
Nb
O
0.00 5.76 15.7 52.2
0.00 8.40 14.7 49.1

PPA:CN Molar Ratio
Based on P:Nb
0
0

PPA Graft
Density (1/nm2)
n.a.
n.a.

PPA+HCN(light)
PPA+TBACN(light)
PPA+TBACN(dark)

3.01
2.28
2.47

3.71
7.94
7.72

11.5
13.6
13.1

42.8
47.0
46.4

0.785
0.504
0.566

2.65
1.70
1.91

PPA+TBACN(dil-DI)
PPA+TBACN(dried, dil-DI)
PPA+TBACN(dried, dil-TBA)

1.64
1.59
1.10

7.69
7.60
7.99

14.1
14.3
14.0

50.5
48.3
50.5

0.349
0.333
0.235

1.18
1.13
0.79

PPA+HCN(dil-Et95)
PPA+HCN(dil-nPr99)
PPA+TBACN(dried, dil-Et95)
PPA+TBACN(dried, dil-Et99)
PPA+TBACN(dried, dil-nPr95)
PPA+TBACN(dried, dil-nPr99)

0.76
1.09
0.70
0.38
0.49
0.71

5.12
4.87
8.71
8.57
8.99
8.67

14.1
13.4
15.3
15.7
15.5
15.0

45.1
43.8
50.7
52.1
51.6
51.2

0.162
0.245
0.138
0.073
0.095
0.142

0.55 (a)
0.83 (a)
0.47
0.25
0.32
0.48

(a) Values reported for consistency; NMR, FT-IR, and TGA data support the conclusion that little or no
PPA grafts onto unexfoliated HCN in alcoholic suspensions. See section 2.3.3.

2.3.2.2. Influence of Light on PPA Grafting
TGA and XRD results presented in Figures 2.2-2.4 demonstrate that adsorbed
TBA+ cations undergo at least partial degradation when TBACN suspensions are exposed
to light, attributed to photocatalytic activity of the layered calcium niobate perovskite.
Does exposure to light affect PPA grafting on TBACN? XRD patterns (Figure 2.6), FTIR spectra (Figure 2.7 and, presented later, Figure 2.16), and TGA data (Figures 2.8 and
2.9) do not reveal significant differences between the product of PPA+TBACN refluxed
in light versus that refluxed in darkness.

XPS results (Table 2.2) indicate that the

PPA:CN molar ratio for PPA+TBACN(dark) is 12% higher than that for
PPA+TBACN(light). For PPA+TBACN(dark), the TGA mass loss in the 350-550°C
temperature range (Figure 2.8a) is about 9% higher than that for PPA+TBACN(light).
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This may seem counterintuitive, since photo-degradation of TBA+ should open up space
on the TBACN surface for additional PPA grafting.
However, the
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P MAS NMR spectra (Figure 2.5c and d) provide evidence that

some grafted PPA may undergo TBACN-catalyzed photo-degradation, which accounts
for the lower PPA grafted amount in PPA+TBACN refluxed in light. The upfield shift of
the peak in Figure 2.5d suggests that for PPA+TBACN refluxed in darkness, PPA grafts
primarily in a bidentate grafting mode (deconvolution into two peaks may not be
justified). The same probably occurs in PPA+TBACN refluxed in light. However, for
PPA+TBACN(light), prolonged light exposure (3 days) under acidic, aqueous reflux
conditions may result in some PPA photo-degradation, accompanied by reversion of a
fraction of bidentate grafts to monodentate form. This rationalizes the two separate
deconvoluted peaks (with upfield shifts corresponding to a mixture of mono- and
bidentate grafts) observed in the NMR spectrum (Figure 2.5c) for PPA+TBACN(light).
PPA grafting modes are discussed more thoroughly in section 2.3.2.4.

2.3.2.3. Effect of Suspension Processing Conditions on PPA Grafting
This section explores the effect of suspension processing steps, such as dilution or
drying and re-dispersion, on PPA grafting onto TBACN platelets. Figure 2.12 displays
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P MAS NMR spectra for washed, dried PPA+TBACN products made from TBACN

suspensions processed in different ways. Each spectrum has a dominant monomodal
peak centered at just above 11 ppm. This upfield shift of about 10.4 ppm (relative to
PPA’s peak at 21.4 ppm, Figure 2.5a) shows that PPA has been grafted onto TBACN.
The PPA signature peak does not appear in Figure 2.12, indicating the absence of non-
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grafted PPA. These results demonstrate that PPA grafting occurs in TBACN suspensions
diluted into DI water or dried and re-dispersed in DI water or TBA solution.
XPS and XRD results (Table 2.2, Figure 2.13) indicate that the location and
amount of PPA grafting are affected by suspension processing conditions. For TBACN
stock suspension diluted 1:1 into DI water [TBACN(dil-DI)], DLS (Table 2.1) shows that
the TBACN platelets are well dispersed, if not fully exfoliated [67]. Thus, PPA has
access to all of the CN platelet surfaces in this case. After PPA grafting, the product
[PPA+TBACN(dil-DI)] has a PPA:CN ratio of 0.349 (Table 2.2), indicating less PPA
grafting than in the PPA+TBACN(light, dark) products discussed earlier. The PPA
concentration in PPA+TBACN(dil-DI) is only half that in the PPA+TBACN(light, dark)
cases. This reduces the driving force for PPA grafting, resulting in the lower PPA:CN
ratio.

The XRD pattern for the PPA+TBACN(dil-DI) product (Figure 2.13) has a

relatively broad peak centered near 5.1°. The peak shape suggests weak turbostratic
ordering with considerable polydispersity of interlayer spacing centered at 1.72 nm. The
product (after drying) has a d-spacing less than that of PPA+TBACN(light, dark) (2.122.17 nm, Figure 2.6), also consistent with the lower PPA grafted amount.
For TBACN suspension that is first dried and then re-dispersed/diluted in DI
water [TBACN(dried, dil-DI)], DLS (Table 2.1) shows that TBACN platelets do not fully
re-disperse,

but

remain

partially

aggregated.

After

PPA

grafting,

the

PPA+TBACN(dried, dil-DI) product has a PPA:CN ratio of 0.333 (Table 2.2),
comparable to that of the PPA+TBACN(dil-DI) product. This indicates that the TBACN
aggregates are sufficiently open to allow PPA access to the platelets’ surfaces over the
three-day reaction period. The 31P MAS NMR spectrum for the PPA+TBACN(dried, dil-
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DI) product (Figure 2.12b) confirms PPA grafting, but the XRD pattern (Figure 2.13) has
no peak (other than residual non-exfoliated HCN), and thus no evidence of CN platelet
ordering in the dried product. If the suspension initially contained disordered aggregates
of TBACN before PPA grafting, then the lack of layering order in the dried
PPA+TBACN(dried, dil-DI) product seems reasonable.
Finally, for TBACN stock suspension dried and then re-dispersed/diluted into
TBA solution [TBACN(dried, dil-TBA)], DLS (Table 2.1) again shows that the TBACN
platelets are well dispersed, as expected, with all face surfaces accessible to PPA. After
adding PPA (3:1 molar ratio to CN unit cells), its concentration is again one-half of that
in the PPA+TBACN(light, dark) samples. However, because TBACN(dried, dil-TBA)
was dried and then re-dispersed into fresh TBA solution, the TBA+:CN ratio was 2:1,
double that of the starting TBACN stock suspension. The lower driving force for PPA
grafting and the greater competition from TBA+ for the CN surface result in a lower PPA
grafted amount: PPA:CN is 0.235 (Table 2.2) for PPA+TBACN(dried, dil-TBA). The
XRD pattern for this product (Figure 2.13) again has a relatively broad peak centered
near 5.1°, consistent with turbostratic ordering and a polydispersity of d-spacing centered
at 1.73 nm. Despite the lower PPA grafted amount, grafting still appears to occur on the
face surfaces of exfoliated TBACN platelets.

Upon drying, the platelets in

PPA+TBACN(dried, dil-TBA) restack with turbostratic order and a mean d-spacing less
than that of TBACN (2.48 nm) or PPA+TBACN(light, dark) (2.12-2.17 nm), but more
than that of the starting HCN (1.48 nm).
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Figure 2.12. 31P MAS NMR spectra with peak fitting for PPA+TBACN products
prepared using TBACN suspensions processed in various ways: PPA added to (a)
TBACN diluted 1:1 with DI water [PPA+TBACN(dil-DI)]; (b) TBACN dried and redispersed in DI water [PPA+TBACN(dried, dil-DI)]; and (c) TBACN dried and redispersed in TBA solution [PPA+TBACN(dried, dil-TBA)]. The resulting suspensions
all had the same TBACN wt% and 3:1 PPA:CN ratio, and all were refluxed in light.
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Figure 2.13. XRD patterns for TBACN and PPA+TBACN products prepared using
TBACN suspensions processed in various ways: PPA added to TBACN diluted 1:1 with
DI water [PPA+TBACN(dil-DI)]; PPA added to TBACN dried and re-dispersed in DI
water [PPA+TBACN(dried, dil-DI)]; and PPA added to TBACN dried and re-dispersed
in TBA solution [PPA+TBACN(dried, dil-TBA)]. The curve for PPA+TBACN(dil-DI)
is shifted upwards for clarity.
The 31P MAS NMR results provide another piece of evidence suggesting that the
driving force for PPA grafting is lower in the diluted suspensions. For PPA grafting in
TBACN suspension dried and re-dispersed in TBA solution [PPA+TBACN(dried, dilTBA)], the NMR spectrum (Figure 2.12c) has an additional peak at -11.5 ppm, consistent
with the production of polyphosphate or polyphosphonate species [22, 23, 104, 106]. To
reiterate, in this reaction mixture, the TBA:CN ratio is 100% higher (2:1) than in TBACN
stock suspension, but the PPA concentration is 50% lower. The adsorbed TBA+ presents
a more formidable steric barrier that may inhibit PPA grafting, especially when the PPA
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concentration is low.

Some of the PPA may oligomerize in solution to form

poly(phenylphosphonate) esters that may be adsorbed or grafted on the CN platelets.
Alternately, the forcing conditions may result in the production of a small amount of
precipitated calcium phenylphosphonate [23, 89, 94, 95, 107].
TGA results for PPA+TBACN products prepared using diluted or dried/redispersed TBACN suspensions are consistent with the NMR, XPS, and XRD results.
Figure 2.14 shows the TGA mass losses and loss rates for PPA+TBACN products
prepared using diluted or dried/re-dispersed TBACN suspensions. In all three cases, the
mass losses of the PPA+TBACN products over 150-700°C (values in Figure 2.15) are
less than the corresponding values (Figure 2.3) for TBACN suspensions processed the
same way, but containing no PPA. This tells us that these PPA+TBACN products
contain less TBA+ than the corresponding TBACN suspensions processed the same way,
but containing no PPA, implying that the PPA grafting process facilitated the removal of
TBA+ from the CN platelets. More TBA+ remained on the CN platelets when the stock
suspensions were simply diluted and refluxed (Figure 2.3) in the absence of PPA.
The mass loss and derivative mass loss curves (Figure 2.14) show that these
PPA+TBACN products have significant mass losses and accelerated mass loss rates in
the 350-550°C range, which must be due primarily to grafted PPA.

However, the

amounts of grafted PPA are less than those found for PPA grafted in more concentrated
suspensions (Figure 2.8a). For PPA+TBACN prepared in TBACN suspension that had
been dried and re-dispersed in DI water (Figure 2.14a), the total (150-700°C) and 350550°C mass losses are higher than the other two cases. This suggests that PPA may
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preferentially partition into, and graft within the TBACN aggregates present in this
suspension.
The shapes of the derivative curves in Figure 2.14b suggest that these
PPA+TBACN products contain some residual TBA+ or byproducts of its photodegradation. This is consistent with the view that for grafting in diluted suspensions,
there is less driving force for PPA to displace the adsorbed TBA+. Figure 2.15 provides
values of the mass losses for these PPA+TBACN products over the key temperature
ranges. Comparison with Figure 2.9 suggests that the PPA+TBACN products prepared
in diluted or dried/re-dispersed suspensions contain both grafted PPA and residual TBA+.
The total amounts of organics are less than that in the starting TBACN (indicating loss of
TBA+). However, the presence of both PPA and residual TBA+ (or its degradation
byproducts) make it difficult to extract more quantitative information on their relative
amounts in these products.
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Figure 2.14. TGA characterization of mass percentage (a) and its derivative (b) as
functions of temperature for PPA+TBACN products prepared using TBACN suspensions
processed in various ways: PPA added to TBACN diluted 1:1 in DI water
[PPA+TBACN(dil-DI)]; PPA added to TBACN dried and re-dispersed in DI water
[PPA+TBACN(dried, dil-DI)]; and PPA added to TBACN dried and re-dispersed in TBA
solution [PPA+TBACN(dried, dil-TBA)]. The starting suspensions all had the same
TBACN wt%, PPA added at 3:1 PPA:CN ratio, and then refluxed in light. Numbers in
(a) indicate mass percentage decreases from 350°C to 550°C.
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Figure 2.15. Fractional mass losses measured by TGA for PPA+TBACN products
prepared using aqueous TBACN suspensions processed in various ways: PPA added to
TBACN diluted 1:1 in DI water [PPA+TBACN(dil-DI)]; PPA added to TBACN dried
and re-dispersed in DI water [PPA+TBACN(dried, dil-DI)]; and PPA added to TBACN
dried and re-dispersed in TBA solution [PPA+TBACN(dried, dil-TBA)]. The starting
suspensions all had the same TBACN wt%, PPA added at 3:1 PPA:CN ratio, and were
refluxed in light. The decimal values are the fractional mass losses over 150-700°C; the
percentages of the 150-700°C mass loss in the 150-350°C and 350-550°C ranges are
shown above each bar.
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2.3.2.4. PPA Grafting Modes
Phenylphosphonic acid has three functional groups (two P-OH and one P=O)
available for covalent bonding with CN, with a total of five possible grafting modes (two
monodentate, two bidentate, and one tridentate) [89, 108-114].
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P MAS NMR, FT-IR,

and XPS spectra can aid in identifying the dominant grafting modes for different
experimental conditions.
PPA and HCN. The FT-IR spectrum for pure PPA (Figure 2.16) agrees with
those previously published [115, 116]; band assignments may be found within these
references.

The FT-IR spectrum for as-prepared HCN has a shoulder at 779 cm-1

identified [103] as the bridging Nb-O-Nb stretching vibration; split peaks at 904 and 942
cm-1 associated with the terminal Nb-O stretching vibration [103]; and the H-O-H
bending vibration at 1635 cm-1. The only significant overlap of PPA and CN bands lies
in the 900-950 cm-1 range, where two of PPA’s P-O stretching vibrations [116] overlap
with the aforementioned CN terminal Nb-O stretching vibration [103]. Figure 2.16 also
shows the spectra for three PPA+CN products; Table 2.3 lists the tentative band
assignments based on the relevant literature.
PPA+HCN. The PPA+HCN product has the same bands as HCN, except that the
HCN peak at 904 cm-1 appears as a shoulder in PPA+HCN. This may be due to an
overlapping peak at 940 cm-1 usually ascribed to a P-O stretch [115, 116]. PPA+HCN
has distinctive peaks at 1153 cm-1 (probably P-C stretch), 1439 cm-1 (aromatic C-C),
1597 cm-1 (weak, aromatic C-C), and 3059 cm-1 (aromatic C-H stretch, not shown), all
indicative of PPA grafting. This spectrum also shows a strong, broad band in the 12001250 cm-1 range due to the P=O stretch (refs. in Table 2.3). The survival of this group
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tells us that PPA grafting in PPA+HCN primarily involves PPA’s P-OH groups. The
PPA+HCN spectrum also shows a broad band in the 975-1100 cm-1 range normally
associated with a variety of P-O stretching vibrations (refs. in Table 2.3). The lack of
distinct peaks in this range probably indicates a distribution of Nb-O-P grafts, as one
might expect for PPA grafting on edges and faces of unexfoliated HCN particles.
The
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P MAS NMR spectrum for PPA+HCN (Figure 2.5b) can be deconvoluted

into three overlapping peaks centered at 17.7, 11.5, and 4.6 ppm. Increasing upfield
shifts (to lower ppm values) are consistent with stronger binding or grafting modes [108].
Thus these three peaks could represent mono-, bi-, and tridentate PPA grafting; as
observed for PPA grafting onto amorphous zirconia and titania [23, 24, 88, 89, 107, 111].
The occurrence of bidentate grafting with P=O surviving might be expected at the edges
of CN platelets where “broken” niobate octahedra expose Nb-(OH)2 sites available for
PPA grafting via condensation with P-OH groups. The availability of Nb-(OH)2 sites
also facilitates the formation of tridentate-grafted PPA, which does not seem to occur
much for PPA grafting onto TBACN face surfaces.
PPA+TBACN. For the products of PPA grafting onto exfoliated TBACN, the FTIR spectra have the same vibrational bands for grafting in light or darkness (Figure 2.16),
and for various suspension processing conditions (Figure 2.17). All of the PPA+TBACN
spectra inherit the 779 and 942 cm-1 bands from HCN. The HCN 904 cm-1 band,
however, is either weak or absent, perhaps due to reaction of PPA with terminal Nb-O
groups. The 904 cm-1 band may also be hidden by the superposition of the HCN 942 cm-1
band and the P-OH bands at 930 and 945 cm-1, inherited from PPA. This would suggest
that residual P-OH groups survive after mono- or bidentate PPA grafting.
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Figure 2.16. FT-IR spectra for (bottom to top): PPA; HCN; PPA+HCN refluxed in DI
water and in light; PPA+TBACN refluxed in darkness; and PPA+TBACN refluxed in
light. Spectra are shifted vertically; and the PPA spectrum rescaled, for visual clarity.
Table 2.3 lists band (peak) assignments.
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Figure 2.17. FT-IR spectra for (bottom to top): PPA; HCN; PPA+TBACN dried and redispersed in TBA solution [PPA+TBACN(dried, dil-TBA)]; PPA+TBACN diluted 1:1 in
DI water [PPA+TBACN(dil-DI)]; and PPA+TBACN dried and re-dispersed in DI water
[PPA+TBACN(dried, dil-DI)]. The starting suspensions all had the same TBACN wt%,
PPA added at 3:1 PPA:CN ratio, and were refluxed in light. Spectra are shifted
vertically; and the PPA spectrum rescaled, for visual clarity. Table 2.3 lists band (peak)
assignments.
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Table 2.3. Band assignments for numbered peaks in the FT-IR spectra shown in Figures
2.16, 2.17, 2.25, and 2.28.

No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

σ (cm-1)
691 (sh)
748
779 (sh)
904
942
962
975-1100
1145, 1153
1220
1379
1439
1462
1484
1597
1636

Source
PPA
PPA
HCN
HCN
HCN
PPA+HCN
PPA
PPA
PPA
TBA+
PPA
TBA+
TBA+
PPA
H2O

Mode (a)
C-H oop
C-H oop
Nb-O bridge
Nb-O term.
Nb-O term.
Nb-O-P
P-O
P-C
P=O
aliph. C-H
arom. C-C
aliph. C-H
aliph. C-H
arom. C-C
H-O-H bend

References
[37, 58, 115, 117, 118]
[37, 58, 117, 118]
[103]
[103]
[103]
this work
[20, 22, 23, 31, 58, 115, 116, 117, 119, 120]
[22, 23, 116, 120]
[20, 22, 23, 31, 58, 115, 116, 119, 121]
[96]
[115, 116, 117, 118]
[96]
[96]
[116]
[96, 103]

(a) Abbreviations: oop = out-of-plane bending; sh = shoulder; term. = terminal; aliph. = aliphatic; arom. =
aromatic.

The PPA+TBACN spectra exhibit various vibrational bands (C-H, C-C, P-C)
expected due to the presence of grafted PPA. We see almost no absorbance due to the
P=O band (1200-1250 cm-1) in the PPA+TBACN spectra, indicating the primary role of
P=O in the grafting of PPA onto TBACN [20, 22, 23, 58, 121]. In the 975-1100 cm-1
range, PPA has a series of distinctive P-O bands (refs. in Table 2.3). In PPA+TBACN,
this wavenumber range has several distinct, overlapping peaks (996, 1018, 1036, 1052
cm-1) also attributed to various P-O vibrations, including those of PO32- and HPO31[115]. The presence of P-OH and Nb-O-P vibrational bands is also likely, but we cannot
make definitive assignments for these bands. Lastly, the spectra in Figure 2.16 for
PPA+TBACN products have a distinct peak at 962 cm-1 (peak 6) that does not appear in
the spectra for PPA, HCN, or PPA+HCN. Shimada et al. [58] ascribed a band at ~950
cm-1 to P-OH, but it seems more likely due to Nb-O-C in their starting material,
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lanthanum niobate with interlayer-grafted decanol. In PPA+TBACN, the absence of the
terminal Nb-O band at 904 cm-1 and appearance of the 962 cm-1 peak suggests that the
latter may be a stretching vibration of Nb-O-P.
31

P MAS NMR spectra for PPA+TBACN products (Figures 2.5 and 2.12) show

that experimental conditions influence PPA grafting modes.

For PPA grafting on

TBACN in the light (Figure 2.5c), the NMR spectrum may be deconvoluted into two
peaks, one smaller and one larger centered at 16.4 and 10.7 ppm, respectively. These
peaks likely correspond to mono- and bidentate grafting modes involving P=O
(primarily) and some P-OH groups. Although the FT-IR band(s) for residual P-OH
groups cannot be conclusively identified, locations at 945 cm-1 and in the 975-1100 cm-1
range seem plausible. The blend of mono- and bidentate grafting can be rationalized in
two ways. As mentioned earlier, PPA initially grafted in bidentate mode may, upon
prolonged exposure to light during reflux, undergo TBACN-catalyzed photo-degradation,
resulting in reversion of some bidentate grafts to monodentate form. Alternately, over
time, photo-degradation of adsorbed TBA+ could free some space on the TBACN
surface, permitting additional PPA grafting in the monodentate mode via P=O reaction
with niobate Lewis acid sites.
For PPA grafted onto TBACN in the darkness (Figure 2.5d), the peak in the NMR
spectrum may be deconvoluted into two closely overlapping peaks (13.1 and 10.8 ppm).
The overall upfield shift suggests primarily bidentate grafting, and the two peaks could
correspond to different bidentate modes (bridged and chelated, vide infra).

The

bidentate-chelating mode may be somewhat more prevalent in this case due to the steric
hindrance of adsorbed TBA+.
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The PPA graft density may also be a relevant factor. For the PPA+TBACN(light,
dark) products, the PPA:CN molar ratios are greater than 0.5 (Table 2.2), which is half of
the maximum ratio assuming 100% bidentate grafting (PPA:CN = 1.0). PPA+TBACN
products prepared in diluted TBACN suspensions have lower PPA graft densities
(PPA:CN ratios between 0.24 and 0.35, Table 2.2) due to the lower PPA concentration
and driving force for grafting. The
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P MAS NMR spectra for these products (Figure

2.12) have one main peak centered in the 11.1-11.6 ppm range, associated (as argued
above) with the bidentate grafting mode.

These spectra also appear to have small

secondary peaks centered in the 3-5 ppm range, possibly consistent with the tridentate
grafting mode. The lower graft density may make it easier for bidentate-grafted PPA
molecules to find an open neighboring site for a third covalent bond. However, the large
majority of the PPA molecules appear to be grafted in the bidentate mode.
The complexity of the FT-IR band structures in the 975-1100 cm-1 range and the
overlap of PPA and HCN bands (Figure 2.16) make it difficult to conclusively assign any
band to P-OH in the FT-IR spectra of the PPA+TBACN products. On the other hand,
XPS O1s spectra (Figures 2.18-2.20) provide strong qualitative evidence for the presence
of surviving P-OH groups in the PPA+TBACN products. Specifically, deconvolution of
the XPS O1s spectrum for PPA (Figure 2.18) gives two peaks at 531.1 and 532.5 eV with
a 1:2 area ratio, consistent with P=O and P-OH, respectively [112, 122-125]. The O1s
spectrum for HCN (Figure 2.18), similar to that found previously [126], can be
deconvoluted into two peaks at 530.0 and 531.4 eV, which we ascribe to bridging Nb-ONb and terminal Nb-OH. The P-OH peak from PPA (532.5 eV) does not appear in the
HCN spectrum, but it does appear in the O1s spectra of all the PPA+TBACN products

56

(Figures 2.19 and 2.20). This shows that at least some P-OH groups survive the grafting
process.

Variations in PPA grafted amounts and sampling depth preclude a more

quantitative analysis based on peak areas. Nonetheless, the XPS O1s results support our
argument that PPA grafts onto the face surfaces of TBA-exfoliated CN platelets primarily
in the bidentate mode.

Figure 2.18. XPS O1s spectra for PPA (top) and as-prepared HCN (bottom).
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Figure 2.19.
XPS O1s spectra for:
PPA+HCN; PPA+TBACN(light); and
PPA+TBACN(dark), as indicated in each plot.
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Figure 2.20. XPS O1s spectra for: PPA+TBACN diluted 1:1 in DI water
[PPA+TBACN(dil-DI)]; PPA+TBACN dried and re-dispersed in DI water
[PPA+TBACN(dried, dil-DI)]; and PPA+TBACN dried and re-dispersed in TBA
solution [PPA+TBACN(dried, dil-TBA)].
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Figure 2.21 illustrates a proposed mechanism, consistent with the results
presented, for grafting of PPA (and possibly other organophosphonic acids) onto the face
surfaces of crystalline, protonated calcium niobate (HCN) layers. Grafting begins with
the coordination of the PPA’s phosphoryl oxygen with a surface Nb atom, a Lewis acid
site, accompanied by cleavage of a Nb-O-Nb bridging bond in the HCN lattice. Similar
reactions have been previously proposed for cleavage of Si-O [17], Al-O [22], Ti-O [23],
and other kinds of metal-oxygen bonds in metal oxides [114].

Initial monodentate

grafting is then followed by secondary heterocondensation between P-OH and apical NbOH groups, producing bidentate grafts with either bridging or chelating modes.
Geometric considerations favor both bidentate modes. Based on PPA bond distances and
angles derived from molecular simulations [93], the distance between O atoms in O=P-OH is about 2.62 Å. Considering the surface atoms in a layer of HCN (Figure 2.22), the
Nb atoms reside in a square array with an Nb-O-Nb distance of 3.855 Å [105] and a
diagonal distance of 5.452 Å. Thus the HCN surface can readily accommodate PPA
grafting in the bidentate-bridging mode with Nb-O-P-O-Nb spanning either the side or
diagonal of the square Nb atom array, depending on the Nb-O-P bond angles. The
bidentate-chelating mode may form when the graft density is high because it does not
require an adjacent apical Nb-OH site.
Geometric considerations do not appear to favor additional heterocondensation
reactions of bidentate-grafted PPA to produce tridentate grafts. The geometry of the
octahedral niobate lattice would require considerable deformation of (approximately)
tetrahedral PPA to form the third leg of a tridentate graft. Evidence of surviving P-OH
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groups from XPS O1s spectra (and possibly FT-IR spectra) appear to rule out extensive
tridentate grafting.
In summary, the proposed mechanism in Figure 2.21 accounts for the primary role
of P=O in grafting, as indicated by the absence of P=O groups in the FT-IR spectra of all
PPA+TBACN

products.

The

mechanism

also

illustrates

how

secondary

heterocondensation may produce two kinds of bidentate grafts, depending on the
availability of adjacent sites. The coordination of Nb remains at six in this mechanism,
avoiding a concern about seven-fold coordination raised in the one previous study of PPA
interlayer grafting on a niobate [58].
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Figure 2.21. Schematic illustration of a proposed mechanism for organophosphonic acid
grafting onto the surface of HCN. Filled and open circles denote Nb and O atoms
respectively in the crystal structure of HCN layers; only surface Nb atoms are shown, and
most O atoms in the HCN lattice are omitted for clarity.
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Figure 2.22. Perspective view of the HCN surface showing the top layer of Nb and O
atoms (blue and red, respectively). The Nb atoms reside on a square lattice with Nb-ONb distance of 3.855 Å; this is also the distance between adjacent apical O atoms. The
diagonal distance between two Nb atoms in the square array is 5.452 Å. Other selected
Nb-O and O-O distances are indicated on the diagram.
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2.3.3. PPA Grafting in HCN and TBACN Alcoholic Suspensions
This section explores PPA grafting onto HCN and TBACN in alcohol-based
suspensions, specifically ethanol and n-propanol at 95% and 99% (balance water).
PPA+HCN. PPA grafting on unexfoliated HCN in ethanol and n-propanol was
examined. Figure 2.23 shows the 31P MAS NMR spectra for the washed, dried products
of refluxing PPA with as-prepared HCN dispersed in these alcohols. For 95% ethanol
(Figure 2.23a), peaks that indicate PPA grafting do not appear, perhaps due to the limited
sample amount. For 99% n-propanol (Figure 2.23b), a small monomodal peak centered
at 13 ppm appears, an upfield shift of about 8.4 ppm relative to the signature PPA peak at
21.4 ppm (Figure 2.5a). The presence of a weak peak indicates at least a small amount of
PPA grafting. The signature peak of PPA does not appear in Figure 2.23, indicating the
absence of non-grafted PPA, which was presumably washed out of the product in the
cleaning stage. XPS results (Table 2.2) indicate the presence of P in these samples. Both
NMR spectra (Figure 2.23) show peak(s) at about -12 ppm, consistent with non-grafted
polyphosphate or polyphosphonate species [22, 23, 104, 106]. This could be rationalized
in terms of PPA-PPA condensation to form polyphosphate due to prolonged reflux, or
attack of HCN by PPA to form niobium phenylphosphonate [23, 89, 107].
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Figure 2.23. 31P MAS NMR spectra for: (a) PPA+HCN refluxed in 95% ethanol, and
(b) PPA+HCN refluxed in 99% n-propanol. Suspensions were refluxed in light. PPA
was added to CN in a 3:1 molar ratio.

65

Figure 2.24a shows TGA results for PPA+HCN in 95% ethanol or 99% npropanol. The total mass loss and loss rate curves are almost the same as those of asprepared HCN (Figure 2.1a). Compared to PPA+HCN grafting in DI water (Figure 2.8a),
the mass losses in the 350-550°C range for PPA+HCN in 95% ethanol or 99% npropanol (Figure 2.24a) are nearly zero.

Apparently PPA surface grafting to non-

exfoliated HCN is not as favorable, perhaps because PPA and HCN are not welldispersed in alcohols based on visual observation and DLS results in Table 2.1.
Figure 2.24b shows XRD patterns for the washed, dried PPA+HCN alcohol
products, along with the pattern for as-prepared HCN. The patterns for PPA+HCN
refluxed in alcohols show a small peak consistent with the starting HCN, but with lower
intensity. There are no XRD peaks at lower angles. This shows that PPA does not
uniformly penetrate and expand the HCN interlayer space, as previously found for PPA
grafting onto a layered niobate that had been “pre-expanded” by grafted decanol [58].
Thus the XRD patterns do not provide any conclusive information on whether or not PPA
grafts onto HCN face surfaces in alcoholic suspensions. The FT-IR spectra for these
products (Figure 2.25) do not indicate the presence of grafted PPA in these samples.
In summary, these results support the conclusion that only small amounts of PPA
graft onto HCN in ethanol or n-propanol suspensions. The location of PPA grafting is
inconclusive.
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Figure 2.24. Characterization of PPA+HCN refluxed in 95% ethanol [PPA+HCN(dilEt95)] and 99% n-propanol [PPA+HCN(dil-nPr99)]: (a) mass percentage and its
derivative as functions of temperature from TGA, and (b) XRD patterns over the lowangle range. Suspensions were refluxed in light. Numbers in (a) indicate mass
percentage decreases from 350°C to 550°C.
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Figure 2.25. FT-IR spectra for (bottom to top): PPA; HCN; PPA+HCN dispersed in
99% n-propanol [PPA+HCN(dil-nPr99)]; and PPA+HCN dispersed in 95% ethanol
[PPA+HCN(dil-Et95)]. Suspensions were refluxed in light. Peak assignments are
described in Table 2.3. Spectra are shifted vertically; and the PPA spectrum rescaled, for
visual clarity.
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PPA+TBACN. DLS (Table 2.1) shows that direct dilution of TBACN suspension
to 5.0×10-5 g/mL in 95% ethanol [TBACN(dil-Et95)] results in a stable alcoholic
suspension of exfoliated TBACN platelets. However, drying TBACN and re-dispersing
in alcohols results in particle sizes larger than that of exfoliated platelets. This shows that
dried TBACN does not re-exfoliate in alcohols, but instead incompletely disperses as
disordered aggregates, resembling TBACN dried and re-dispersed in DI water
[TBACN(dried, dil-DI)].
Figure 2.26 shows 31P MAS NMR spectra for the washed, dried products of PPA
added to TBACN that was dried and re-dispersed in alcohols. For grafting in ethanol
(95% and 99%, Figure 2.26a and b, respectively), the spectra of the PPA+TBACN
products have monomodal peaks centered between 14-16 ppm, an upfield shift of ~6-7
ppm relative to PPA. This demonstrates that PPA grafts onto TBACN dispersed in
ethanol. The spectra do not manifest peaks at 21 ppm indicative of non-grafted PPA,
signifying that all of the detected PPA has been grafted. XPS results (Table 2.2) imply
that the PPA grafted amounts on TBACN in ethanol are about 65% less than in aqueous
TBACN suspensions. The XRD patterns (Figure 2.27) for these samples have small
peaks at angles corresponding to a d-spacing of about 1.5 nm, probably due to residual,
non-exfoliated HCN. Otherwise, the absence of any distinctive peaks is consistent with
dried aggregates lacking any turbostratic ordering.
The magnitude of the upfield shifts of the peaks in the
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P MAS NMR spectra

suggest that PPA grafting on TBACN in ethanol produces primarily monodentate grafted
PPA [23, 89, 107, 121]. The FT-IR spectra for these products (Figure 2.28) do not show
any indication of bands at 1220 cm-1, indicating that P=O groups do not survive the
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grafting process. The spectra show distinct shoulders near 962 cm-1, consistent, in our
view, with the formation of Nb-O-P linkages. However, the survival of P-OH groups
cannot be definitively established either by FT-IR or XPS O1s spectra. Still, PPA
grafting onto TBACN in ethanol appears to follow at least the first step of the mechanism
proposed in Figure 2.21.
For PPA grafting onto TBACN in n-propanol, the 31P MAS NMR spectra (Figure
2.26c and d) also indicate PPA grafting, although the grafted amounts (from XPS, Table
2.2) are smaller than in aqueous TBACN suspensions. For grafting in 95% n-propanol
(Figure 2.26c), the dominant peak at ~11 ppm suggests that PPA grafts onto TBACN
primarily in the bidentate mode. A small peak near 4 ppm may indicate some tridentate
grafting, or perhaps just noise in the data. For grafting in 99% n-propanol (Figure 2.26d),
the NMR spectrum can be deconvoluted into two peaks at 16.5 and 11 ppm. This
suggests the presence of both monodentate and bidentate grafting modes. The FT-IR
spectra (Figure 2.28) for the products refluxed in n-propanol are similar to those for
ethanol: no band for P=O survives the grafting process. Thus, PPA grafts onto TBACN
(in n-propanol) via the P=O group, consistent with the first reaction in Figure 2.21.
All of the
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P MAS NMR spectra in Figure 2.26 could have overlapping peaks

that could not be deconvoluted due to the low grafted amounts and weak NMR signals.
Thus, all of the PPA+TBACN products refluxed in alcohols could have a mixture of PPA
grafting modes that may not be apparent in Figure 2.26. The peaks at about -11 ppm in
Figure 2.26b and c are again consistent with PPA undergoing a reaction other than with
TBACN. This reaction may produce polyphosphate or polyphosphonate species [22, 23,
104, 106], or precipitated calcium phenylphosphonate [23, 89, 94, 95, 107].
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Figure 2.26. 31P MAS NMR spectra with peak fitting for PPA+TBACN products
prepared using TBACN suspensions dried and re-dispersed in alcohol solvents: (a)
PPA+TBACN dried and re-dispersed in 95% ethanol [PPA+TBACN(dried, dil-Et95)];
(b) PPA+TBACN dried and re-dispersed in 99% ethanol [PPA+TBACN(dried, dilEt99)]; (c) PPA+TBACN dried and re-dispersed in 95% n-propanol
[PPA+TBACN(dried, dil-nPr95)]; and (d) PPA+TBACN dried and re-dispersed in 99%
n-propanol [PPA+TBACN(dried, dil-nPr99)]. The resulting suspensions all had the same
TBACN wt% and 3:1 PPA:CN ratio, and all were refluxed in light.
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Figure 2.27. XRD patterns for PPA+TBACN products prepared using TBACN
suspensions dried and re-dispersed in alcohol solvents: PPA+TBACN dried and redispersed in 95% ethanol [PPA+TBACN(dried, dil-Et95)]; PPA+TBACN dried and redispersed in 99% ethanol [PPA+TBACN(dried, dil-Et99)]; PPA+TBACN dried and redispersed in 95% n-propanol [PPA+TBACN(dried, dil-nPr95)]; and PPA+TBACN dried
and re-dispersed in 99% n-propanol [PPA+TBACN(dried, dil-nPr99)]. The resulting
suspensions all had the same TBACN wt% and 3:1 PPA:CN ratio, and all were refluxed
in light.
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Figure 2.28. FT-IR spectra for (bottom to top): PPA; HCN; PPA+TBACN dried and redispersed in 99% n-propanol [PPA+TBACN(dried, dil-nPr99)]; PPA+TBACN dried and
re-dispersed in 95% n-propanol [PPA+TBACN(dried, dil-nPr95)]; PPA+TBACN dried
and re-dispersed in 95% ethanol [PPA+TBACN(dried, dil-Et95)]; and PPA+TBACN
dried and re-dispersed in 99% ethanol [PPA+TBACN(dried, dil-Et99)].
Peak
assignments are described in Table 2.3. Spectra are shifted vertically; and the PPA
spectrum rescaled, for visual clarity.
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Figure 2.29. Fractional mass losses measured by TGA for PPA+TBACN products
prepared using alcoholic TBACN suspensions: PPA+TBACN dried and re-dispersed in
95% ethanol [PPA+TBACN(dried, dil-Et95)]; PPA+TBACN dried and re-dispersed in
99% ethanol [PPA+TBACN(dried, dil-Et99)]; PPA+TBACN dried and re-dispersed in
95% n-propanol [PPA+TBACN(dried, dil-nPr95)]; and PPA+TBACN dried and redispersed in 99% n-propanol [PPA+TBACN(dried, dil-nPr99)].
The resulting
suspensions all had the same TBACN wt% and 3:1 PPA:CN ratio, and all were refluxed
in light. The decimal values are the fractional mass losses over 150-700°C; the
percentages of the 150-700°C mass loss in the 150-350°C and 350-550°C ranges are
shown above each bar.
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2.4. Conclusions
This work shows that phenylphosphonate (PPA) can be covalently grafted onto
protonated calcium niobate (HCN). PPA grafts onto the face surfaces of TBA-exfoliated
HCN (TBACN) dispersed in deionized water, TBA solution, ethanol, and n-propanol.
However, PPA does not penetrate and graft in HCN’s interlayer spaces, but grafts only
onto the exterior surfaces of unexfoliated HCN. This work contrasts with other recent
reports of interlayer PPA grafting onto niobate sheets that were “pre-expanded” by
interlayer grafted decanol [58, 127]. We believe that this is the first report of organic
molecule grafting, and certainly organophosphonic acid grafting, onto the face surfaces
of exfoliated, niobate-based platelets. Kimura et al. [127] recently reported interlayer
PPA grafting on layered hexaniobates, followed by exfoliation in organic solvents. The
present work represents the first report of organic molecule grafting onto layered niobate
perovskites in aqueous suspensions.
Various characterization results confirm not only the grafting of PPA on
exfoliated TBACN, but also quantify the PPA grafted amount and identify the grafting
mode (mono-, bi-, and tridentate).

The PPA grafting location and grafted amount

depends on the exfoliation/aggregation state of TBACN, suspension processing
conditions, and solvent composition. Due to the photocatalytic properties of the layered
calcium niobate perovskite, the state of light/darkness probably plays some role in the
grafting process. In the starting TBACN suspensions, adsorbed TBA+ cations undergo
photo-degradation under reflux conditions in light, but not in darkness. PPA seems to
graft onto TBACN primarily in the bidentate mode, but prolonged exposure in light may
result in some PPA degradation and/or reversion of some bidentate grafts to the
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monodentate form. A mechanism proposed for PPA grafting onto HCN and TBACN
seems to account for all experimental observations.
The demonstration of PPA grafting onto exfoliated, TBA-exchanged HCN in
aqueous and organic solvents may be the first step towards the synthesis of more
sophisticated organo-functional niobate platelets. For example, grafting phosphonatebased initiators or chain transfer agents, followed by surface-initiated polymerization,
could lead to polymer-grafted platelets (PGPs). Ultimately, PGPs could be used as
building blocks for fabrication of polymer nanocomposites with tailored end-use
performance for automotive, aerospace, and energy applications.
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Chapter

3:

Effect

of

Interfacial

Pretreatment

on

the

Properties

of

Montmorillonite/Poly(vinyl alcohol) Nanocomposites

Unlike calcium niobate, montmorillonite (MMT) was shown in Chapter 1 to be
able to readily disperse in aqueous suspensions without needing additional help. Thus,
MMT can be straightforwardly incorporated into polymer nanocomposites (PNCs)
consisting of poly(vinyl alcohol) (PVOH) matrix utilizing the solution blending
technique. Previous research discovered, however, that the properties of the resulting
PNCs are not as “ideal” as one would expect. It is believed that this is due to bridging
between polymer chains adsorbed on the surface of neighboring MMT platelets
producing aggregates. Chapter 3 explores the effect of “pretreating” the MMT surface
with a small amount of a low-weight, compatible polymer before adding in the polymer
matrix to counter polymer bridging. Characterization results compare two pretreatment
methods with untreated MMT and the corresponding neat polymer matrix.

3.1. Introduction
PNCs are increasingly utilized in automotive, aerospace, energy, and flame
retardant applications.

PNCs may offer significant performance advantages over

traditional polymer composites, including: (1) enhanced physical properties; (2) ability
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to tailor material properties for new applications; (3) improved performance/weight ratio
achieved by reduction of filler loadings from 15-40 vol% to as little as 1-5%; and, (4)
improved processing performance.
Advances in the fundamental understanding of the role of the filler-polymer
interface (really an “interphase”) have driven growth in PNC applications. As discussed
in many reviews of PNC research [128-145], the interphase has distinct properties that
are amplified by the high interfacial area/volume ratio achieved when the filler particles
have nanoscale dimensions. The properties of the interphase also control the dispersion
state of the nanoparticles in the polymer. Poor nanoparticle dispersion reduces interfacial
area and thus the contribution of the interphase to the composite properties.
Consequently, achieving enhanced nanocomposite properties and performance depends
critically on maximizing nanoparticle dispersion in the polymer.
The challenge lies in overcoming attractive particle-particle interactions
responsible for filler aggregation. Considerable research has focused on the design of
filler-polymer interphases to maximize nanoparticle dispersion in polymers [140-141,
146-153]. For example, early work on clay/polymer PNCs utilized cation exchange
treatment of clay minerals with alkylammonium salts to make the clay platelets more
hydrophobic and (in principle) more compatible with polymers [128-132, 134, 139, 143144]. More recent work explores covalent grafting of polymers on particles for tailoring
interphase properties and particle dispersion [146, 149-153]. Work to date has primarily
emphasized tailoring the interphase to control nanoparticle dispersion in polymers. Less
attention has been given to evaluating the “direct” contribution of the particle-polymer
interphase to PNC properties [148, 154].
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Consider, for example, the well-studied PNC consisting of exfoliated
montmorillonite (MMT) platelets dispersed in poly(vinyl alcohol) (PVOH) [155-164].
Using a suitable cleaning protocol [165], aqueous suspensions of fully-exfoliated MMT
can be prepared without the need for dispersants. PVOH is water-soluble and readily
adsorbs onto MMT [166-172]. These facts suggest that MMT and PVOH are naturally
compatible. Using the solution-blending method [155-158, 160-164], one should be able
to prepare “model” or “ideal” nanocomposites consisting of fully-exfoliated MMT
platelets randomly dispersed in a PVOH matrix.
In many cases, the barrier properties of “ideal” MMT/PVOH PNCs fall short of
what one might expect based on the “tortuous path” model [173-176]. For example,
values of water vapor permeability [155] and diffusivity [160] in MMT/PVOH
composites (with MMT loadings up to 6 wt%) were found to be about 60% lower than
those in pure PVOH.

Yeh et al. [158] observed that water vapor and oxygen

permeabilities in MMT/PVOH PNCs initially decreased with increasing MMT loading,
but then increased significantly above 5 wt% MMT. Grunlan et al. [161] found the
opposite trend: depending on relative humidity, oxygen permeability in MMT/PVOH
initially increased with MMT loading, reaching a maximum at about 3 wt%, before
decreasing at higher loadings. These observations are not only inconsistent, but also
disagree with predictions of various tortuous path models, all of which predict sharp,
monotonic decreases in gas permeability with increasing platelet loading. These gas
permeation studies reveal that our idealized picture of internal structure in exfoliated
PNCs must not be complete.
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At least two factors may complicate our picture of how structure develops in
MMT/PVOH nanocomposites during solution blending and densification of the parent
solutions. First, the dissolved PVOH may induce MMT inter-platelet attraction, either
through bridging adsorption [166, 168, 171-172, 177-180] or depletion flocculation [168,
177, 180-181]. Second, PVOH may undergo gelation or de-mixing during densification,
opening up the possibility of MMT partitioning into a preferred phase [182-184]. These
factors have not been considered in previous studies of MMT/PVOH nanocomposites.
We have found that exfoliated MMT platelets tend to re-stack or aggregate at
some point during the solution blending and densification processes that transform MMT
and PVOH solutions into a solid MMT/PVOH nanocomposite. The objective of this
work is to explore the role of MMT platelet interactions on platelet dispersion in
MMT/PVOH nanocomposites prepared by solution blending. The first part of this work
demonstrates that MMT platelet re-stacking takes place during the solution blending
process. The second part investigates a novel concept, MMT surface “pretreatment” by
adsorption of low molecular weight homopolymer (PVOH) or block copolymer (F108
Pluronic®) from a dilute solution. This pretreatment may prevent bridging flocculation
by blocking the MMT surface before solution blending with the PVOH matrix polymer.
We assess the impact of MMT pretreatment on platelet dispersion as well as the thermal,
mechanical, and gas barrier performance of MMT/PVOH nanocomposites.
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3.2. Experimental
3.2.1. Preparation of MMT Suspensions
Stock suspensions of fully-exfoliated MMT (Cloisite Na+, Southern Clay
Products, Inc.) were prepared following our published procedure [165]. Typically, the
as-received MMT powder is dispersed at 1.0 wt% in deionized (DI) water, mixed at room
temperature for at least 12 h, sonicated for 30 min (Fischer-Scientific FS-28), centrifuged
at 4000 rpm (2000 g) for 60 min (fixed-angle Eppendorf 5403 centrifuge), followed by
careful decanting of the supernatant suspension.

The product suspension typically

contains about 0.75 wt% MMT (batch-to-batch values ranging from 0.60 to 0.90 wt%) as
measured by dry weight analysis. Our previous AFM study [165] shows that the MMT
platelets in these suspensions are essentially fully exfoliated; histograms of MMT platelet
thickness and aspect ratio (Figures 3.2 and 3.3) can be found in the Results and
Discussion, section 3.4.1. [185].
The stock MMT suspension is used to prepare two kinds of pretreated MMT
platelet suspensions as well as PVOH nanocomposite films. To prepare MMT pretreated
with low molecular weight PVOH (11-31 kDa, 98-99% hydrolyzed, Alfa Aesar, used as
received; denoted below as PV11), stock MMT suspension is added drop wise to an
aqueous solution of PV11 with heating (~90°C) and mixing for at least 60 min. The
MMT suspension should be added to the PVOH solution, rather than vice-versa, to
minimize bridging flocculation. The PV11 solution concentration and the volume of
added MMT suspension are adjusted so that the mixture contains 0.50 wt% PV11, and that
the total solids content (i.e., polymer + MMT) is 64.3% PV11 and 35.7% MMT by
weight.

The latter figure must be taken into account when the PV11-treated MMT
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(denoted henceforth as PV11MMT) is solution-blended with additional matrix PVOH to
prepare nanocomposites with precisely 10.0 wt% MMT loading.
For the second pretreated MMT suspension, we add MMT suspension drop wise
to an aqueous solution of F108 Pluronic®, a triblock copolymer surfactant (14,600 Da,
BASF, used as received) with at least 60 min mixing at room temperature. Both the
central poly(propylene oxide) block (DP=44) [186] and the two poly(ethylene oxide) end
blocks (DP=141) [187] may adsorb on the MMT surface. The MMT suspension and
F108 solution volumes are adjusted so that the mixture has a total solids content of 75%
MMT and 25% F108 by weight, with a 0.10 wt% F108 concentration. The F108-treated
MMT is denoted henceforth as F-MMT.

3.2.2. Preparation of MMT/PVOH Nanocomposite Films
MMT/PVOH nanocomposite films were prepared using low, medium, and high
molecular weight PVOH: PV11, PV95 (95 kDa, 95% hydrolyzed, Acros Organics, used as
received), and PV205 (205 kDa, 99+% hydrolyzed, Sigma Aldrich, used as received).
Aqueous PVOH solutions are prepared by dissolution of PVOH powders in DI water
with mixing at 90°C for at least 60 min. To prepare nanocomposites with 10 wt% nonpretreated MMT, an appropriate volume of stock MMT suspension is added drop wise to
the warm PVOH solutions so that the final, blended suspension contains an overall
PVOH concentration of 5.0 wt% and (on a solids-only basis) 10.0 wt% MMT and 90.0
wt% PVOH.
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Solution blending of pretreated MMT suspensions (PV11MMT or F-MMT) with
PVOH solutions proceeds in the same way. Suspensions of pretreated MMT were used
as prepared, so one must account for the pretreatment polymer content in the blending
process. The volume and concentration of PVOH solution must be adjusted so that the
total polymer content (PVOH matrix plus PVOH or F108 carried by the pretreated MMT)
is precisely 90 wt% in the final composites. The starting PVOH solution also has a lower
initial concentration so that the final blended suspension has a total polymer
concentration of about 2.0 wt%. Sample “recipes” are provided in Appendix A.
Solution casting or drawdown coating was used to make nanocomposite films.
Solution cast films were prepared by depositing a known mass of blended suspension
onto an aluminum pan and drying in air in an oven at either 40°C or 120°C (annealing).
For drawdown coating, typically 3 to 5 mL of blend suspension was deposited onto a
Mylar® sheet (supported by a balanced glass plate underneath) and drawn down using a
doctor blade. A Microm II film applicator (Gardco) was configured with a doctor blade
gap distance set to 1 mil (25.4 μm) in order to control the thickness of the final film.
Sliding the blade slowly forms a wet film coating. The plate is then carefully covered
with a shield to minimize settling of dust particles onto the wet film. The drawn films
were dried at room temperature for one day, gently peeled from the Mylar sheet, dried
overnight in a vacuum oven at 60°C, and then stored in a sealed desiccator. The final
films typically have a thickness of 20 to 30 µm as measured using a micrometer
[Mitutoyo Digimatic Micrometer MDC-MX, model 293-831].
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3.3. Characterization Methods
Transmission Electron Microscopy (TEM)
Electron microscopy employed a Hitachi H-8000 transmission electron
microscope (TEM). To prepare a specimen for TEM observation, it was first trimmed to
the shape of the cross-section of a BEEM® conical embedding capsule. After placing the
film sample in the capsule center (with the film tip aligned with the capsule tip, tip
pointing down), a premixed epoxy resin was slowly poured in to embed the sample. The
capsule was closed and the epoxy cured at 80°C for 24 h. After curing, the tip of the
formed epoxy block was trimmed to expose the sample tip. The tip was then sectioned
into several ~100 nm thin slices using an Ultra 35° diamond knife at room temperature.
The floating slices were collected from water using carbon coated steel grids, air dried,
then observed by TEM under an accelerating voltage of 200 KeV.

X-Ray Diffraction (XRD)
X-ray diffraction (XRD) utilized a Rigaku Ultima IV diffractometer (Cu Kα
radiation, λ=1.5418Å). Small angle measurements used an incidence angle (ω) of 0.5°,
divergence slit (DS) set at 0.1 mm, and scanned over a 2θ range of 0.2° to 10°. For wide
angle scans (2θ from 2° to 50°), the DS was set at 0.2 mm. For both angular ranges,
scans used a step size of 0.05° and a scan speed of 2 degrees/min. XRD samples were
prepared by drawdown coating of films directly onto transparent glass slides with drying
at room temperature.
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Dynamic Light Scattering (DLS)
DLS measurements employed two instruments:

DynaPro Titan (Wyatt

Instruments) and Zetasizer Nano ZS ZEN3600 (Malvern Instruments). Both instruments
have a temperature-control system to monitor the size of MMT nanoplatelets in dilute
suspensions from samples taken throughout the film-making process. This information
can determine the state of the MMT dispersion by evaluating for the extent of
aggregation within the PVOH matrix. All DLS measurements start by sizing at 25°C a
standard of 0.24 μm polystyrene latex uniform microspheres (Bangs Laboratories, Inc.)
diluted in DI water to a solids weight fraction of either ~5.0×10-5 (Malvern) or ~5.0×10-6
(Wyatt) as a preliminary check. The DLS results for both instruments are in reasonably
good agreement with the nominal listed size.
Similarly, MMT suspensions or dissolved MMT/PVOH films were also diluted in
DI water to the same respective weight fraction corresponding to the instrument used.
These values were chosen as a benchmark at 25°C between a too concentrated
polystyrene standard and a too dilute MMT suspension of known sizes to equate for
accurate and consistent DLS measurements. Temperature control was set to keep the
viscosity of the water constant, while the beam intensity was also individually controlled
depending on the instrument. Samples of aqueous MMT suspensions were diluted with
DI water to a weight fraction of about 5.0×10-6 (Wyatt). Samples of cast films were
dissolved in DI water and characterized by DLS (Malvern) to provide an indirect measure
of MMT aggregation. Film samples were dissolved via mixing for at least 24 h in DI
water at temperatures ranging from room temperature up to 70°C. The MMT weight
fraction was approximately 5.0×10-5 in these samples.
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Because DLS theory for platelet-shape particles is not well understood, a
quadratic cumulants method with an intensity autocorrelation function was used to “fit”
the MMT as polydisperse spheres. This determines the z-average translational diffusion
coefficient, which is then used in the Stokes-Einstein equation to compute the equivalent
“hydrodynamic diameter” of the MMT nanoplatelets.

Thermal Properties
Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA)
were used to evaluate the thermal properties of nanocomposite films. For DSC (Q2000,
TA Instruments), approximately 5 mg of sample (cast film dried at 40°C) was tightly
packed into a Tzero aluminum pan (TA Instruments) and then sealed. Two identical
heating/cooling cycles (40-240°C, 10°C/min scan rate) were conducted under nitrogen
purge. For TGA (Q5000, TA Instruments), approximately 8-10 mg of sample (cast film
dried at 40°C) was placed onto a high-temperature platinum pan (TA Instruments) and
heated in air to 800°C at a scan rate of 10°C/min.

Mechanical Properties
Dynamic Mechanical Analysis (DMA) was used to characterize nanocomposite
mechanical properties (RSA-III, TA Instruments). Samples of drawn films were cut into
strips (47-49 mm length, 6-7 mm width, 20-30 µm thickness) and then dried in a vacuum
oven at 60°C for 24 h. Specimens were carefully mounted in the tensile testing fixture
followed by zeroing the pre-tension, heated to 140°C, and held at that temperature for 5
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min. Complex tensile modulus was measured during a temperature sweep from 140°C to
-80°C (-3°C/min ramp rate, 1.0 Hz frequency, 0.05% strain amplitude). At least three
specimens of each nanocomposite were tested.

Gas Permeability
The gas barrier properties of nanocomposite polymer films were measured using a
custom-built gas permeation system (Figure 3.1).

The main components of the

permeation system are a continuous-flow permeation cell, a variable leak valve, and a
quadrupole mass spectrometer (SRS100, Stanford Research Systems). After drying in a
vacuum oven at 60°C for at least 24 h, a drawn film was masked on both sides using
heavy-duty aluminum foil sealed with high vacuum grease, leaving exposed a circular
area of about 5 cm2. The masked film was seated and sealed in the permeation cell. One
side was exposed to the test gas, water vapor at 36.5°C at >97% relative humidity. A
carrier gas (N2) flowed at a controlled mass flow rate over the other side, carrying the
permeate gas into the mass spectrometer for measurement of the permeate concentration.
A mass balance yields the water vapor transmission rate (WVTR).

For each

nanocomposite, WVTR was measured for at least three replicate film specimens.
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Figure 3.1. Schematic diagram depicting our custom-built equipment for measuring gas
permeation through polymer films.

Referring to Figure 3.1, film samples are mounted in the permeation cell
consisting of two metal halves sealed by an O-ring and clamped tightly by nuts and bolts.
Each metal half has a shallow circular cavity in its center. Two chambers are formed
after a test film is mounted between the two metal halves. During operation, one of the
chambers is supplied with the test gas, while the carrier gas continuously sweeps the
other. Both the test gas pressure and the carrier gas flow rate are precisely controlled.
The permeant, i.e., the test gas that has permeated through the test film, is fully mixed
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into the carrier gas stream leaving the permeation cell. The gas permeation rate J(t) is
given by:
J (t )  C(t )  q / A

(1)

where C(t) is the concentration of the test gas in the effluent carrier gas stream at any
instant t, q is the carrier gas flow rate, and A is the permeation area.
A small amount of the effluent carrier gas stream is leaked into the high vacuum
chamber at a controlled rate with the aid of a variable leak valve, while the rest is vented.
Determination of C(t) is made viable by exploiting the fact that under high vacuum, the
characteristic mass-to-charge (m/z) peak generated by the mass spectrometer for a gas
species changes linearly with the change of its partial pressure.

The instrument’s

sensitivity factor for a gas g, denoted as Sg, is defined as:

Sg 

Ig

(2)

pg

where Ig denotes the principal mass-to-charge peak and pg denotes the partial pressure.
This sensitivity factor is fairly constant when the total vacuum pressure is below 10-5 torr.
Dalton’s law relates the partial pressure to concentration, assuming that the vacuum
environment is dominated by the carrier gas. The total vacuum pressure is referenced
from a cold-cathode ionic gauge also attached to the high vacuum chamber. Combining
(1) and (2), the gas permeation rate is given by:

J g (t ) 

q I g (t ) / S g
A p vac

(3)

where pvac is the total vacuum pressure. By definition, the permeability of a film is:
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Pg 

Jg l

(4)

p g

where Jg is the steady-state permeation rate, l is the film thickness, and pg is the applied
partial pressure difference across the film.
The permeation apparatus described here was tested for the case of carbon dioxide
permeation. The specimen films were one-mil thick Mylar PET supplied by Eastman
Chemical Company. The carrier gas was 99.9995% pure argon and the test gas was
99.5% pure carbon dioxide, both from National Welders. Three measurements were
made using the specimens from the same film. The relative standard deviation among the
measurements was 2%.

The permeability results were then compared with

measurements obtained on a MOCON instrument. The differences were found to be
within 6% of the MOCON measurement.
In this work, the carrier gas was nitrogen and the test gas was either oxygen or
water vapor. The sensitivity factor for oxygen was determined by calibration using a
certified gas mixture of 2000 ppm oxygen in carbon dioxide. For comparison purposes,
all permeation tests for a given test gas (oxygen or water vapor) were performed under
the same conditions. Specifically, for oxygen permeation tests, the vacuum pressure was
approximately 2.5×10-6 mbar, the applied oxygen pressure difference was 1 atmosphere,
and temperature was ambient (23~25C). All films for oxygen permeation testing were
dried in vacuum at ~80C for 24 hours and conditioned in argon overnight prior to
testing. TGA results indicated that the films were 99% dry after vacuum-drying.
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For water permeation tests, the sensitivity of the instrument to water was
calibrated using a humidified stream of saturated nitrogen gas. The principal mass-tocharge ion peak of water at m/z = 18 was monitored during the tests. The vacuum
pressure was approximately 1.0×10-6 mbar, the water partial pressure difference was
6150 Pa, and temperature was fixed at 25C.

3.4. Results and Discussion
3.4.1. “Ideal” MMT/PVOH Nanocomposites
Previous research [165] has established purification procedures (described above)
that produce suspensions of almost completely exfoliated montmorillonite (MMT)
platelets, as verified by AFM (Figures 3.2 and 3.3).

Our previous research [185]

describes the use of AFM for quantitative analysis of the size distribution of exfoliated
MMT platelets. For every individual “particle” in each AFM image, we can measure the
vertical dimension relative to the background at every point on each particle. The
average value of the vertical dimension is the mean thickness of that particle. Based on
the typical lateral dimensions seen in the AFM images (10’s to 100’s of nm) and the
median thickness of 1.20 nm, these particles are clearly platelets. The median thickness
of 1.20 nm is consistent with the expected thickness of hydrated MMT platelets.
About 83% of the particles seen in the AFM images have mean thicknesses
between 0.9 nm and 1.5 nm: these are pristine single platelets. If one defines exfoliation
as the production of pristine single platelets, then we would say that this sample is 83%
exfoliated. About 15% of the particles have mean thicknesses between 1.6 and 2.5 nm.
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Typically, these are single platelets with all or part of a second platelet on top (see inset
of Figure 3.2). Even pristine single platelets are often observed to have small fragments
somewhere on their top surface. If the second platelet fragment is large, it may cover
most of the surface of the platelet underneath. This can be called a duplex stack (two
platelets). Strictly speaking, these platelets are not exfoliated. However, we can say that
98% of the MMT particles in this sample are exfoliated into either single platelets or
duplex stacks. We do not see a significant incidence of duplex stacks that appear to be
created due to the random deposition of one pristine single platelet overlapping part of
another single platelet.
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Figure 3.2. Histogram of mean MMT platelet thicknesses based on N=1468 particles
from 39 different AFM images [185]. The inset shows a part of one AFM image
showing mostly pristine single platelets; the arrows point to two particles that are
probably unexfoliated duplex stacks.

For every individual particle in each AFM image, image analysis gives us the
lateral area in nm2 [185]. We compute a characteristic lateral length for each particle as
the square root of the measured area. The particle’s aspect ratio equals the characteristic
lateral length divided by the mean thickness of that individual particle. In this way, we
can measure the exact aspect ratio of every particle in an AFM image. The aspect ratios
of N=1468 particles are compiled in the histogram of Figure 3.3. The mean and median
aspect ratios are 159 and 142, respectively. Multiplying these values by the median
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platelet thickness (1.20 nm) gives an “average” platelet length between 191 and 170 nm.
The measured aspect ratio distribution may be used in conjunction with a recent version
of the tortuous path model [176] to estimate the gas barrier performance of PNC films
containing platelets with considerable size polydispersity.
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Figure 3.3. Histogram of MMT platelet aspect ratio based on N=1468 particles from 39
different AFM images [185].
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This work began with two initial hypotheses.

The first was that “ideal”

MMT/PVOH nanocomposites prepared from suspensions of fully exfoliated MMT
platelets should exhibit superior gas barrier performance compared to that reported
previously [155, 158, 160-161].

Second, by properly accounting for platelet

polydispersity, the tortuous path model [176] should be able to rationalize the measured
gas barrier performance of our supposedly “ideal” MMT/PVOH nanocomposites.
To this end, we prepared a series of MMT/PVOH nanocomposite films with
varying MMT loadings and measured their oxygen permeabilities. Figure 3.4 plots this
data in terms of the O2 barrier factor (the O2 permeability of pure PVOH divided by that
of a MMT/PVOH nanocomposite), along with predictions of the tortuous path model
[176] based on the MMT platelets’ measured aspect ratio distribution (Figure 3.3). The
O2 barrier factor rises monotonically with MMT loading but falls substantially below the
prediction of the tortuous path model for fully exfoliated platelets (curve denoted by
n=1). If we use the same aspect ratio distribution but assume that the dispersed particles
are aggregated platelet “stacks” with an average of four platelets each (curve denoted as
n=4), the model prediction rationalizes the barrier data up to 5 wt% MMT, but
significantly over-predicts barrier performance at higher MMT loadings.
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Figure 3.4. Oxygen barrier factor (symbols) for MMT/PVOH nanocomposites as a
function of MMT loading (95 kDa PVOH matrix). The solid curves are calculated via
the tortuous path model for polydisperse platelets [176] based on the aspect ratio
distribution measured for this MMT by AFM (Figure 3.3). Labels denote calculations
assuming full exfoliation (n=1) and partial aggregation into stacks containing an average
of four platelets (n=4).

The O2 barrier data and comparisons with model predictions essentially invalidate
both of our initial hypotheses. Although the increase in O2 barrier with MMT loading
agrees with expectations, measured barrier performance is not superior to that observed
previously.

Moreover, the differences between measured and predicted barrier

performance indicate flaws in the assumptions of the tortuous path model, flaws in our
concept of “ideal” MMT/PVOH nanocomposites (i.e., that we could prepare fully-
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exfoliated PNCs by blending verified, fully-exfoliated platelet suspensions with solutions
of compatible polymer), or both.
TEM images give qualitative indications of non-idealities in structure that arise
during solution blending, solvent evaporation, and film densification. Away from the
surfaces of a 10 wt% MMT/PVOH composite film, we observe regions of what appear to
be face-aggregated platelets in addition to regions of well-dispersed, individual platelets
(Figure 3.5a). Other TEM images (Figure 3.6) show similar regions in both 1 wt% and
10 wt% MMT/PVOH composites. This shows that although MMT platelets are fully
exfoliated in the starting stock suspension, they undergo at least partial aggregation
during solution blending, solvent evaporation, and film densification. Near the film
surface, we observe what appears to be a wrinkled region of layered, consolidated
platelets (Figures 3.5b and 3.7). The wrinkling could be caused by stresses generated
either during densification or microtoming.

Regardless, the observed platelet

consolidation should not occur if the densification process only involves water removal
from a uniform mixture of PVOH and exfoliated MMT platelets.

Both platelet

aggregation and surface consolidation provide evidence for some kind of platelet-platelet
attraction that arises during solution blending, solvent evaporation, and film
densification.
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Figure 3.5. TEM images of a 10 wt% MMT/PV95 nanocomposite. (a) Interior region
with indicated areas containing well-dispersed platelets (circle) and face-aggregated
platelets (rectangle). (b) Surface region showing a wrinkled “skin” of consolidated
platelets.
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Figure 3.6.
below).

TEM images of interior regions in MMT/PVOH nanocomposites (see
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Figure 3.7.
below).

TEM images of surface regions in MMT/PVOH nanocomposites (see

(a) Low magnification image for 10 wt% MMT/PVOH (092509-PVOH-10wt%MMT80kX).
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(b) Medium magnification image for 10 wt% MMT/PVOH (092509-PVOH10wt%MMT#6E).
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(c) High magnification
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PVOH readily adsorbs onto MMT in water [166-172]. This suggests that PVOHmediated bridging attraction might lead to MMT aggregation during the solution
blending process. Dynamic light scattering data provide some evidence for this. For
diluted MMT stock suspensions (MMT, Figure 3.8), the measured particle size is about
186±9 nm, independent of the MMT concentration after dilution. This DLS particle size
agrees well with the platelets’ characteristic lateral dimension as measured by AFM
(Figure 3.3). MMT stock suspension was then mixed with PV205 solution to produce a
blend suspension (MMT+PV205, Figure 3.8) containing about 0.28 wt% MMT and 5.0
wt% PVOH.

After dilution to the indicated MMT concentrations, the particle size

measured by DLS ranged from 284 to 368 nm (average 317±38 nm) with larger
polydispersity indices. The greater particle size (compared to the starting MMT) results
from a combination of PVOH adsorption and platelet aggregation due to polymer
bridging.
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Figure 3.8. MMT particle size as measured by DLS. MMT: MMT stock suspension
diluted to the indicated MMT weight fraction. MMT+PV205: MMT stock suspension
mixed with PV205 solution to produce a blend suspension containing 0.28 wt% MMT and
5.0 wt% PV205, and then diluted to the indicated MMT weight fraction.

3.4.2. MMT Platelet Pretreatment
The previous results lead to the third hypothesis investigated in this work: that
initially coating MMT platelets with a protective layer of polymer may reduce bridging
attraction between platelets, promote better platelet dispersion, and improve the
properties of MMT/PVOH nanocomposites. We refer to this preliminary coating as
“pretreatment”, considering that the platelets will subsequently undergo blending with
PVOH matrix polymer and then densification to form MMT/PVOH nanocomposites.
To test this hypothesis, we seek a pretreatment polymer that readily adsorbs onto
MMT, has good compatibility with the PVOH matrix, and does not itself produce
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bridging aggregation. High molecular weight PVOH (such as PV205) should adsorb
strongly and provide a thick steric barrier, but it also may promote bridging aggregation
(Figure 3.8). For this reason, we focused on two lower molecular weight pretreatments:
PV11 and F108 Pluronic®, a PEO-PPO-PEO triblock copolymer.

The polymer

concentration used in pretreatment should maximize adsorption and thus the effectiveness
of the steric barrier. On the other hand, if the pretreatment polymer concentration is too
high, then its concentration in the final polymer nanocomposite will be too high, as well
(see Appendix A for details).
MMT was pretreated with PV11 by adding MMT stock suspension to PV11
solutions, producing PV11MMT suspensions with varying PV11 concentration. The MMT
particle size was measured by DLS after dilution with DI water (Figure 3.9). For the
pretreatment suspension containing 0.1 wt% PV11, the large apparent particle size clearly
indicates MMT aggregation.

In this case, PV11 acts as a flocculent:

the low

concentration results in only partial coverage of the MMT surface, enabling PV11
bridging that leads to MMT aggregation. For PV11MMT suspensions with 0.25 wt% and
higher PV11 concentrations, the MMT particle size is consistently about 25% higher than
that in the MMT stock suspension. As in the case of MMT+PV205 (Figure 3.8), the larger
effective particle size may be due to a combination of PV11 adsorption (producing larger
hydrodynamic drag on the diffusing PV11MMT platelets) as well as low levels of MMT
aggregation. However, the higher PV11 concentrations clearly do not result in large-scale
MMT flocculation.
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Figure 3.9. MMT particle size, as measured by DLS, in suspensions containing various
concentrations of PV11. Suspensions were diluted with DI water to MMT weight
fractions of 1.0×10-5 (solid bars) or 5.0×10-6 (hatched bars).
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Among the PV11 solutions listed in Figure 3.9, the pretreatment suspension
containing 0.50 wt% PV11 was selected for preparing nanocomposites in subsequent
solution blending. Depending on the MMT weight fraction in the starting MMT stock
suspension, this pretreatment suspension typically contained 30-40 wt% MMT (on a
solids basis) with the balance as PV11. These quantities must be taken into account in
subsequent solution blending to achieve the target MMT loading (10.0 wt%) in the final
composite (see Appendix A for details).
In addition to PV11, PV95 and PV205 as well as F108 Pluronic® were also explored
for pretreating the MMT surface. DLS characterization was used to measure MMT
particle size in these pretreatment suspensions (Figure 3.10). For MMT pretreated with
F108 at concentrations of 0.1% and 0.5% (F-MMT), the measured MMT particle sizes
were approximately 150 nm, essentially identical to that of the MMT stock suspension.
This indicates that F108 pretreatment does not lead to MMT aggregation. We elected to
use 0.1% F108 for pretreatment to avoid any complications due to micelle formation
[188]. For the MMT pretreated with 0.5% PV95 or PV205, DLS results gave an average
particle size of 235 nm. This suggests that these higher molecular weight polymers
produced some polymer bridging that resulted in some MMT aggregation. Because of
this, PV95 and PV205 were not studied further for use in MMT pretreatment.

110

250

MMT size (nm)

200
150
100
50
0
MMT Stock
Suspension

0.1% F-MMT

0.5% F-MMT

0.5%
PV95MMT

0.5%
PV205MMT

Figure 3.10. MMT particle size as measured by DLS for various pretreatment
suspensions, including F108 (F-MMT), PV95, and PV205, at indicated concentrations.
Suspensions were diluted with DI water to a MMT weight fraction of 5.0×10-6.

Next, we assess the extent to which pretreatment using PV11 or F108 prevents
polymer bridging during solution blending. Figure 3.11 shows the effect of solution
blending on the apparent size of MMT particles, expressed as percentage change relative
to the MMT particle size in the starting stock suspension for each set of experiments. For
the pretreatment suspensions, the average particle sizes in PV11MMT and F-MMT are
about 30% and 0.5% greater, respectively, than that in MMT stock suspension. This may
indicate some bridging aggregation in PV11MMT suspension, which is not observed in FMMT suspension.
Blending untreated MMT stock suspensions with PVOH solutions results in
significant increases in apparent particle size, ranging from 67% for MMT+PV11 to 160%
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for MMT+PV205.

This indicates a strong tendency of PVOH to induce bridging

aggregation of untreated MMT, which increases with polymer molecular weight. For
pretreated PV11MMT suspension blended with PVOH solutions, the particle size only
increases from 40% to 56% with increasing PVOH molecular weight.

Thus, PV11

pretreatment seems to reduce the incidence of bridging aggregation during solution
blending of PV11MMT suspension with PVOH solutions. The dependence on the PVOH
molecular weight is weak. Although thermodynamically favored, PV95 and PV205 do not
displace previously-adsorbed PV11 from the MMT surface on the time scale of these
experiments.
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Figure 3.11. Percentage change in apparent particle size (relative to untreated MMT in
stock suspension) for particles in pretreatment suspensions (“pretreat”) and MMT+PVOH
blend suspensions (2 wt% polymer) with various PVOH molecular weights (PV11, PV95,
and PV205). The legend indicates results for untreated MMT and pretreated PV11MMT
and F-MMT. All samples for DLS were diluted with DI water to an MMT weight
fraction of 5.0×10-6.

We observe a similar trend for solution blending of pretreated F-MMT suspension
with PVOH solutions, but the molecular weight dependence is more pronounced (14%,
49%, and 92% particle size increase upon blending F-MMT with PV11, PV95, and PV205
solutions, respectively). We infer that PV11 does not readily displace “pre-adsorbed”
F108 from the surfaces of F-MMT platelets. On the other hand, higher molecular weight
PV205 appears to be more effective at displacing F108 from the F-MMT surface, resulting
in a higher incidence of bridging aggregation. Overall, these results suggest that F108
may be preferable for pretreating MMT to prevent bridging if the molecular weight of the
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PVOH matrix is low. If the molecular weight of the PVOH matrix is high, then PV11 is
preferable for preventing MMT bridging aggregation during solution blending.

3.4.3. MMT/PVOH Nanocomposite Properties
3.4.3.1. Structural Characterization
XRD measurements provide information on structure within MMT/PVOH
nanocomposites, including the effect of MMT on PVOH crystallinity and the incidence
of platelet restacking. Figure 3.12 shows XRD patterns for the starting MMT powder,
neat PV95 film, and various 10 wt% MMT/PV95 composites. Plots for neat PV11 and
PV205 films and their MMT nanocomposites are shown in Figures 3.13 and 3.14. The
pattern for MMT powder features a prominent (001) peak centered at 7.38°,
corresponding to a layer spacing of 1.20 nm, as expected. The pattern for neat PV95 film
has a broad peak centered at 19.6° that is typically associated with semicrystalline PVOH
structure [155, 156, 159, 164]. The patterns for all of the MMT/PVOH nanocomposites
(Figure 3.12) are similar. First, none of the composite patterns show evidence of a peak
near 7.4° associated with the layered MMT structures, nor any peaks at lower angles due
to expanded or restacked MMT platelets. All of the composite patterns display weak
peaks centered near 9.3°, which we believe to be associated with surface-induced
nucleation of additional PVOH crystallites. This peak has been observed previously
[164, 172, 189], but (in one case) misinterpreted in terms of MMT layer expansion [164].
Our observations suggest that composites prepared with pretreated MMT probably have
structures similar to that seen in untreated MMT/PVOH composites.
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Figure 3.12. XRD patterns for starting MMT powder, neat PV95 film, and various 10
wt% MMT/PV95 composites as labeled in the plot. The intensity upturn at low angles is
due to the underlying glass slide used to mount the polymer films for XRD.
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Figure 3.13. XRD patterns for starting MMT powder, neat PV11 film, and various 10
wt% MMT/PV11 composites as labeled in the plot. The intensity upturn at low angles is
due to the underlying glass slide used to mount the polymer films for XRD.
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Figure 3.14. XRD patterns for starting MMT powder, neat PV205 film, and various 10
wt% MMT/PV205 composites as labeled in the plot. The intensity upturn at low angles is
due to the underlying glass slide used to mount the polymer films for XRD.

3.4.3.2. Thermal and Mechanical Properties
DSC characterization indicates the effect of MMT surface pretreatment on
composite thermal properties. DSC results (Figure 3.15) show that addition of untreated
MMT to PVOH nucleates a new crystalline phase with a higher melting temperature than
that of the neat polymer [155]. This new crystalline phase forms at the MMT/PVOH
interface, accompanied by reduced bulk polymer crystallinity [156]. Our results indicate
that MMT surface pretreatment has some effect on nanocomposite crystallinity. For the
lowest molecular weight PV11 matrix (Figure 3.15a), composites incorporating
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PV11MMT and untreated MMT have essentially the same crystallization curves; this
might be expected since the pretreatment and matrix polymers are the same in the
PV11MMT/PV11 composite. The crystallite melting temperatures are about 5°C lower for
the F-MMT/PV11 composite compared to MMT/PV11.

It also appears that the F-

MMT/PV11 composite has more bulk and less interfacial crystallinity than MMT/PV11.
These observations suggest that adsorbed F108 disrupts the nucleation and growth of
interfacial crystallites in the F-MMT/PV11 composite.
For composites based on the intermediate molecular weight PV95 matrix (Figure
3.15b), MMT pretreatment with PV11 or F108 does not change the total amount of
crystallinity or the relative amounts of bulk and interfacial crystallites. However, the
nature of the pretreatment has an effect on crystallite nucleation. The PV11MMT/PV95
and F-MMT/PV95 composites have crystallization temperatures that are about 5°C higher
and 5°C lower, respectively, than those of untreated MMT/PV95. As found for the FMMT/PV11 composite, the F108 pretreatment appears to disrupt crystallite nucleation in
the F-MMT/PV95 composite. In contrast, PV11 pretreatment appears to promote PV95
crystallite nucleation in the PV11MMT/PV95 composite.
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Figure 3.15. Exothermic heat flow during DSC first cooling scans for: (a) neat PV11
film and various MMT/PV11 composites and (b) neat PV95 film and various MMT/PV95
composites. The solid vertical lines indicate the locations of maxima in the
crystallization peaks for the neat PV11 and PV95 films.
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The highest PVOH molecular weight used in this study, PV205, is less crystalline
than PV11 and PV95. Blending untreated MMT with PV205 appears to reduce the overall
crystallinity in the MMT/PV205 composite compared to neat PV205 film (Figure 3.16), but
exotherms associated with both bulk and interfacial crystallization are observed in the
DSC cooling curve. Compared with the MMT/PV205 composite, those prepared with
both PV11MMT and F-MMT appear to have higher levels of interfacial crystallization
and suppression of bulk polymer crystallization.

Enhancement of interfacial

crystallization seems to be greater in the PV11MMT/PV205 composite.

Figure 3.16. Exothermic heat flow during DSC first cooling scans for neat PV205 film
and various MMT/PV205 composites.
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The effect of MMT pretreatment on composite thermal stability and
decomposition rate has been evaluated by TGA (Figures 3.17-3.19). In all cases, the neat
PVOH films and MMT/PVOH composites lose 3-5% of their mass upon heating to
200°C.

The composites incorporating PV11MMT appear to have somewhat smaller

levels of water loss (Figures 3.17a and 3.18a).

However, the differences are not

significant; measured mass losses vary ±3% in this temperature range. The rate of mass
loss accelerates at about 260°C for neat PV11 and all composites based on PV11.
Likewise, the rate of mass loss accelerates at about the same temperature (~290°C) for
neat PV95 and its composites, as well as neat PV205 and its composites (~280°C). At
higher temperatures, the presence of MMT slows down the thermal decomposition rates
of the composites compared to the corresponding neat polymer films: the increasing
MMT content creates a barrier that hinders the escape of decomposition products.
However, we observe no significant influence of MMT pretreatment on decomposition
rate, compared to composites based on untreated MMT. These TGA observations show
that MMT pretreatment has little effect on the thermal stability and decomposition rate of
MMT/PVOH composites.
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Figure 3.17. TGA mass loss as a function of temperature for neat PV11 film and various
10 wt% MMT/PV11 composites: (a) low temperature range, (b) full temperature range.
In (a), the curve for the PV11MMT/PV11 composite is labeled separately but is not
believed to differ significantly from the other curves.
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Figure 3.18. TGA mass loss as a function of temperature for neat PV95 film and various
10 wt% MMT/PV95 composites: (a) low temperature range, (b) full temperature range.
In (a), the curve for the PV11MMT/PV95 composite is labeled separately but is not
believed to differ significantly from the other curves.
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Figure 3.19. TGA mass loss as a function of temperature for neat PV205 film and various
10 wt% MMT/PV205 composites: (a) low temperature range, (b) full temperature range.
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The effect of MMT pretreatment on composite mechanical properties, namely
storage modulus and loss tangent, has been evaluated via DMA (Figures 3.20-3.24). For
all matrix PVOH molecular weights, blending untreated MMT with PVOH appears to
increase storage modulus (E’) at all temperatures, relative to the neat polymer (Figures
3.20a and 3.21). Considering values measured at 25°C, average E’ values in untreated
MMT/PVOH composites are about 13%, 42%, and 41% higher compared to neat films of
PV11, PV95, and PV205, respectively (Figure 3.22), but the increases are statistically
significant only for PV95 and PV205. There are no statistically significant differences
among the average E’ values for composites incorporating untreated MMT, PV11MMT,
and F-MMT for all matrix PVOH molecular weights.
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Figure 3.20. Storage modulus (a) and loss tangent (b) as functions of temperature for
neat PV95 films, untreated MMT/PV95 composites, and PV11MMT/PV95 composites.

126

(a)
MMT/PV11 (2 replicates)

Storage Modulus (Pa)

1.0E+10

1.0E+09
Neat PV11
(3 replicates)

1.0E+08
-100

-50

0
50
Temperature (°C)

100

150

(b)
MMT/PV205 (2 replicates)

Storage Modulus (Pa)

1.0E+10

1.0E+09

Neat PV205
(2 replicates)

1.0E+08
-100

-50

0
50
Temperature (°C)

100

150

Figure 3.21. Storage modulus as a function of temperature for (a) neat PV11 film and
untreated MMT/PV11 composite, and (b) neat PV205 film and untreated MMT/PV205
composite.
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Figure 3.22. Storage modulus at 25°C for neat PVOH films and various MMT/PVOH
composites. PVOH matrix molecular weight is indicated at the top of each panel; neat
PVOH or filler is indicated below each bar. Error bars are 95% confidence limits based
on 3 to 5 replicates.
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With regard to loss tangent (Figure 3.20b), blending untreated MMT or
PV11MMT with PV95 significantly reduces the magnitude of the loss tangent peak and
shifts the peak temperature downward by about 4°C, relative to the corresponding neat
PV95. Similar trends in loss tangent peak values are observed for neat polymer films and
treated/untreated composites based on PV11 and PV205 (Figures 3.23). Downward shifts
of the peak temperature are significant for all fillers for the PV11 matrix, and for untreated
MMT and PV11MMT for the PV95 matrix (Figure 3.24). Aside from these observations,
there are no other statistically significant differences among the average loss tangent peak
values or the peak temperatures for composites incorporating untreated MMT,
PV11MMT, and F-MMT (Figures 3.23 and 3.24). Overall, the DMA results indicate that
MMT pretreatment has little or no effect on the mechanical properties of MMT/PVOH
composites.
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Figure 3.23. Peak loss tangent for neat PVOH films and various MMT/PVOH
composites. PVOH matrix molecular weight is indicated at the top of each panel; neat
PVOH or filler is indicated below each bar. Error bars are 95% confidence limits based
on 3 to 5 replicates.
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Figure 3.24. Peak loss tangent temperature for neat PVOH films and various
MMT/PVOH composites. PVOH matrix molecular weight is indicated at the top of each
panel; neat PVOH or filler is indicated below each bar. Error bars are 95% confidence
limits based on 3 to 5 replicates.
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3.4.3.3. Gas Barrier Performance
The effect of MMT pretreatment on the gas barrier performance of MMT/PVOH
nanocomposites was investigated by measurements of water vapor transmission rate
(WVTR), expressed in Figure 3.25 as water permeability.

Compared to oxygen

permeation experiments used in our preliminary work (Figure 3.4), water permeation
tests are much faster, more reproducible, and less sensitive to variations in test gas
humidity.

Water permeation testing employed the same experimental apparatus as

described earlier in Section 3.3.
Each group of bars in Figure 3.25 compare water permeabilities through films
composed of the same molecular weight of the PVOH matrix (neat films and
composites). For all PVOH molecular weights, there is no significant difference (at the
95% confidence level) between the permeabilities of untreated MMT/PVOH composites
and the corresponding neat PVOH film. For the low molecular weight PV11 matrix, the
untreated MMT/PV11 composite has higher water permeability than the neat polymer
films at the 86% confidence level. We conclude that for MMT/PVOH composite films
made by solution blending, addition of 10 wt% untreated MMT does not improve water
barrier performance, and may even increase water permeability relative to neat polymer.
Considering composites prepared with pretreated MMT, Figure 3.25 shows that
films incorporating either PV11MMT or F-MMT have reduced water permeability values
relative to neat PVOH and untreated MMT/PVOH composites. The statistical confidence
levels for this observation vary among the data sets. For the lower and intermediate
molecular weight PV11 and PV95 matrix polymers, permeability values for films with
pretreated MMT are lower than those for the corresponding neat PVOH and untreated
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MMT/PVOH composites with greater than 95% confidence levels. The exception among
these is F-MMT/PV11 compared to neat PV11: the former has a lower permeability with
82% confidence.
For the high molecular weight PV205 matrix polymer, the trend is the same, but
with lower levels of statistical confidence. The average water permeability values of
PV11MMT/PV205 and F-MMT/PV205 composite films are lower than that of untreated
MMT/PV205 with greater than 90% confidence, and lower than that of neat PV205 film
with 70-80% confidence.

For all three PVOH molecular weights, we observe no

significant difference in water permeability values between PV11MMT and F-MMT
composites.
The results for PV11MMT-based composites are particularly remarkable.
Pretreating MMT with PV11, and then blending this suspension with the identical PV11 as
the polymer matrix, produces a composite film with approximately one-third the water
permeability (or three-fold barrier improvement) compared to a composite film prepared
simply by blending untreated MMT with PV11 matrix. The composite compositions are
identical, but the preparation process varies, with profound consequences on a
macroscopic property, water permeability.
Moreover, this unambiguously illustrates the distinct influence of polymer/platelet
interfacial nanostructure on a macroscale composite property (water permeability). For
adsorption of low molecular weight PV11 onto MMT from dilute solutions (as in the
pretreatment

process),

PV11

molecules adsorb primarily in

flattened “train”

configurations [178] with most segments contacting the MMT surface. Such adsorbed
PV11 layers are thin but have high surface coverage; this minimizes bridging aggregation
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during pretreatment. In contrast, adsorption of PV11 from much higher concentration
solutions (as in the blending process) results in more extended “loop” and “tail”
configurations that leave more of the MMT surface exposed [178]. If the hydrophilic
MMT surface (essentially a defect in the polymer matrix) facilitates water transport in
MMT/PVOH composites, then the high MMT surface coverage resulting from PV11
pretreatment may be effective in blocking interfacial water transport, thus reducing water
permeability relative to that in untreated MMT/PVOH composites.
The overall conclusion is that MMT pretreatment with either PV11 or F108 results
in composite films with improved water barrier performance compared to composites
containing untreated MMT, as well as compared to pure polymer films. This appears to
be especially significant for composites made with low to moderate molecular weight
PVOH matrices. In general, the results suggest that polymer interfacial nanostructure
plays a significant, explicit role in water transport in MMT/PVOH composites.
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Figure 3.25. Water permeabilities in PVOH and MMT/PVOH films of low, medium,
and high molecular weight polymer (PV11, PV95, PV205). Within each group, bars from
left to right denote results for neat PVOH and composites incorporating untreated MMT,
PV11MMT, and F-MMT. Error bars are 95% confidence limits.

3.4.3.4. Film Dissolution Behavior
Film dissolution behavior was studied by suspending pieces of composite films in
DI water with stirring and modest heating, followed by dilution with DI water and DLS
measurement of the average particle size. Consider (1) an “ideal” nanocomposite in
which the matrix polymer adheres strongly to the filler nanoparticles, and (2) dissolution
utilizing excess solvent that readily solubilizes the polymer and forms stable suspensions
of re-dispersed filler nanoparticles. The particles released from the dissolved film ought
to be somewhat larger than the starting filler nanoparticles, with the incremental size
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increase due to the hydrodynamic effect of adsorbed polymer. In practice, the difference
between the final and the initial nanoparticle size may be quite large due to incomplete
dissolution, i.e., incomplete polymer-particle de-aggregation.

Sufficient dilution can

eliminate the possibility of large particle aggregates due to depletion flocculation.
Assuming that thermodynamics favors complete polymer dissolution and particle redispersion, the root cause of incomplete dispersion probably lies in polymer-mediated
bridging interactions between particles.
The MMT/PVOH system should be “ideal”:

PVOH is water-soluble, fully-

exfoliated MMT suspensions can be prepared, and PVOH strongly adsorbs onto MMT.
DLS results presented earlier (Figure 3.11) show that polymer bridging may occur during
solution blending of untreated MMT suspensions with PVOH solutions.

However,

pretreatment with low molecular weight PVOH (PV11) or F108 mitigates polymer
bridging, at least in part, during solution blending. The film dissolution study aims to
characterize, at least qualitatively, the effect of MMT pretreatment on polymer bridging
during the film densification and drying steps.
To this end, we prepared solution-cast film samples that were dried, re-dissolved
in DI water, diluted to a pre-determined MMT weight fraction, and then characterized by
DLS. Two drying protocols were investigated. In the first, the cast films were air-dried
in an oven at 40°C. The resulting “dried” films still contained significant amounts of
residual water, approximately 2 to 4 wt% based on TGA data (Figures 3.17a-3.19a). In
the second drying protocol, the cast films were “annealed” by air-drying in an oven at
120°C, reducing the water content of the films to about 1 wt% or less (estimated from
TGA data).
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Figure 3.26a shows DLS particle size measurements for suspensions produced by
dissolving MMT/PVOH composite films that had been dried at 40°C. In all cases, the
size difference values show that none of the films had undergone complete, “ideal”
dissolution into constituent dissolved PVOH and re-suspended MMT particles.
Considering the untreated MMT/PVOH composites first, the particle size difference
decreases as the molecular weight of the PVOH matrix increases.

For the highest

molecular weight PV205 matrix, the density and thickness of the adsorbed steric barrier
may be sufficient to minimize aggregation due to polymer bridging and van der Waals
attraction. Film dissolution releases individual MMT platelets and small aggregates that
may have been present in the blending suspension; hence the measured size difference is
relatively small.
For the untreated MMT/PV95 and MMT/PV11 composites, the polymer adsorbed
amount (molecules per unit MMT surface area) and adsorbed layer thickness decrease
with decreasing PVOH molecular weight [178, 190]. Thinner adsorbed polymer layers
permit closer interactions among MMT platelets in consolidated films, resulting in
increased polymer bridging and van der Waals attraction. Upon immersion in water, the
MMT aggregates do not disperse as thoroughly, resulting in measured particle size
differences that increase with decreasing PVOH matrix molecular weight (Figure 3.26a).
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Figure 3.26. Particle size difference (relative to MMT particle size in stock suspension,
measured by DLS) for MMT particles released from MMT/PVOH composite films
dissolved in DI water. (a) Film samples dried at 40°C. (b) Film samples annealed at
120°C. Category labels indicate low, medium, and high molecular weight polymer
matrix (PV11, PV95, PV205). Within each group, bars from left to right denote results for
composites incorporating untreated MMT, PV11MMT, and F-MMT. Error bars are 95%
confidence limits. In all cases, the dissolved film suspensions were diluted to a MMT
weight fraction of 5.0×10-5 in DI water.
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Pretreating MMT with PV11 or F108 has a remarkable effect on film dissolution
behavior (Figure 3.26a). For PV11MMT/PV11, the average size of particles released from
the dissolved film is almost 200 nm smaller than that of particles released from the
dissolved, untreated MMT/PV11 composite. In other words, if one pretreats MMT with
PV11 and then blends this suspension with identical PV11 as the matrix polymer, the
resulting film dissolves more completely than films prepared by simply blending
untreated MMT with PV11.
This observation can be rationalized, once again, in terms of the nanoscale
polymer structure at the MMT/PVOH interface.

During MMT pretreatment, PV11

molecules adsorbing from dilute solution assume flattened “train” configurations. This
results in high coverage of the MMT surface, making aggregation due to polymer
bridging less likely.

Moreover, during solution blending, incoming PV11 matrix

molecules are less likely to adsorb on the pretreated PV11MMT surface, further
mitigating polymer bridging aggregation. The PV11 matrix still maintains a steric barrier
between nearby MMT platelets.

Thus, upon PV11MMT/PV11 film dissolution, the

released particle aggregates are smaller than those released from dissolved, untreated
MMT/PV11. During blending of untreated MMT with higher concentrations of PV11
solution, PV11 molecules adsorb in more extended “loop/tail” configurations.

This

surface structure permits more polymer bridging between neighboring platelets during
film densification, and thus less complete dissolution when the final film is exposed to
water.
Considering the treated F-MMT/PV11 composite (Figure 3.26a), particles released
during film dissolution are only about 100 nm smaller than those released from the
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untreated MMT/PV11 composite, and about 100 nm larger than particles released from
the treated PV11MMT/PV11 composite. This implies that F108 does not protect the MMT
surface against PV11 bridging as effectively as pre-adsorbed PV11. This again can be
rationalized in terms of interfacial structure. F108 is a triblock copolymer that may
adsorb onto MMT in a more extended configuration than PV11, making the MMT surface
more accessible to incoming matrix PV11 molecules during the blending process.
The film dissolution behavior seen for composites based on PV11 matrix polymer
also applies to PV95 composites (Figure 3.26a). Particles released during the dissolution
of PV11MMT/PV95 and F-MMT/PV95 composites are about 180 nm and 120 nm smaller,
respectively, than particles released during the dissolution of MMT/PV95 composite. In
fact, the particles released by the dissolution of PV11MMT/PV95 film are only 50 nm
larger than that of the starting MMT platelets used in the composite’s synthesis. These
results show that PV11 and F108 are both effective pretreatments for mitigating polymer
bridging during densification of PV95-based composites.
In contrast, PV11 and F108 pretreatments do not have much impact on the film
dissolution behavior of composites based on the higher molecular weight PV205 matrix
polymer (Figure 3.26a).

The relatively small particle size difference for untreated

MMT/PV205 (about 100 nm relative to the starting MMT platelet size) indicates that
PV205 adsorption onto untreated MMT produces a steric barrier thick enough to
significantly reduce polymer bridging during film densification. MMT pretreatment with
PV11 and F108 does not have much impact, possibly due to the displacement of these
lower molecular weight molecules during adsorption of higher molecular weight PV205.
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Figure 3.26b shows DLS particle size measurements for suspensions produced by
dissolution of MMT/PVOH composite films annealed at 120°C. For composites based
on low molecular weight PV11 matrix polymer, DLS results show that the particles
released by film dissolution are more than 1000 nm larger than the starting MMT
platelets. Moreover, MMT pretreatment has no significant impact on film dissolution
behavior. In practice, these films do not easily dissolve in water, even with extended
stirring and heating. For the higher molecular weight PV95 and PV205 matrix polymers,
the released particles are 115-225 nm larger than the starting MMT platelets, indicating
more facile film dissolution in these cases. Once again, however, we observe that MMT
pretreatment has no significant impact on film dissolution behavior.
These observations can also be rationalized in terms of MMT/PVOH interfacial
structure and its dependence on PVOH molecular weight. TGA shows that heating
MMT/PVOH composites from 40°C to 120°C results in weight losses of 2-4% (Figures
3.17a-3.19a), almost certainly due to the removal of residual water. Much of this water
probably came from the vicinity of the surfaces of the hydrophilic MMT platelets. The
residual water occupied space on the MMT surfaces and associated with PVOH
molecules, presumably through hydrogen bonding.

Removal of the residual water

certainly resulted in significant changes in the polymer’s interfacial structure, primarily
consolidation of the adsorbed polymer layers due to additional binding to the MMT
surface. For low molecular weight PV11 matrix polymer, this leads to MMT plateletplatelet adhesion due to both polymer bridging and van der Waals attraction, making it
very difficult to de-aggregate and re-disperse the MMT. On the other hand, the higher
molecular weight PV95 and PV205 matrix polymers adsorb to form thicker layers on

141

MMT. Even when the residual water is removed, the thicker steric barriers help mitigate
both polymer bridging and van der Waals attraction, making it easier to de-aggregate and
re-disperse the MMT platelets.

3.5. Conclusions
In this work, a low molecular weight PVOH (PV11) and a PEO-PPO-PEO triblock
copolymer (F108 Pluronic®) were studied as pretreatments to modify the surface of
exfoliated MMT platelets prior to solution blending with PVOH matrices of varying
molecular weight. DLS (Figure 3.11) shows that pretreating MMT with PV11 or F108
limits platelet aggregation during solution blending, especially as matrix PVOH
molecular weight increases. XRD gave no indication of MMT platelet re-stacking or any
variations in polymer crystallinity due to MMT pretreatment.

DSC revealed that

PV11MMT seemed to promote interfacial nucleation of matrix PVOH, while F-MMT
seemed to generally have the opposite effect. Both TGA and DMA suggested that MMT
pretreatment had no significant effect on composite thermal stability and mechanical
properties, respectively.
On the other hand, MMT pretreatment does have a significant impact on water
permeation in MMT/PVOH nanocomposites (Figure 3.25). By occupying polar water
binding sites on the hydrophilic MMT surface, PV11 and F108 may impede water
transport along the MMT surface, thus enhancing barrier performance. Film dissolution
studies also show that MMT pretreatment also influences the dissolution behavior of
partially-dried, non-annealed MMT/PVOH composite films. Both the water barrier and
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film dissolution results show that the local nanostructure at the PVOH-MMT interface
may be altered by pretreatment with PV11 and F108, producing significant changes in
macroscopic properties. Direct comparison of results for PV11MMT/PV11 and untreated
MMT/PV11 show that even though the composite compositions are identical, variations in
processing details can have a major impact on composite properties and performance.
These observations may be significant for polymer nanocomposite applications in the
packaging industry.
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Appendix A: Typical Solution Blending Recipes
MMT stock suspension weight fraction =

0.009058

Untreated MMT/PVOH Blends Recipe
Material

Amount

%
Solids

DI Water

9.933 g

PVOH matrix

1.500 g

90.0%

Dry MMT solids

0.167 g

10.0%

Volume of MMT stock required

18.400 ml

Total:

30.000 g

100.0%

%
Polymer

5.0%

5.0%

Note: MMT stock is in water

0.5% PV11MMT Stock Suspension Recipe
Material

Amount

DI Water

%
Solids

%
Polymer

85.719 g

PV11

0.625 g

64.3%

Dry MMT solids

0.347 g

35.7%

Volume of MMT stock required

0.5%

38.309 ml

Total:

125.000 g
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100.0%

0.5%

PV11MMT/PVOH Blends Recipe
Material

Amount

DI Water

%
Solids

%
Polymer

8.200 g
[Total Polymer]

0.534 g

PVOH matrix

90.0%

0.427 g

PV11MMT stock

1.78%
1.42%

21.373 g
[PV11]

0.107 g

[Dry MMT solids]

0.059 g

10.0%

30.000 g

100.0%

Total:

0.36%

1.78%

Note: [] are not added to the blend

0.1% F-MMT Stock Suspension Recipe
Material

Amount

DI Water

%
Solids

%
Polymer

83.100 g

F108

0.125 g

25.0%

Dry MMT solids

0.375 g

75.0%

Volume of MMT stock required

0.1%

41.400 ml

Total:

125.000 g
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100.0%

0.1%

F-MMT/PVOH Blends Recipe
Material

Amount

DI Water

%
Solids

%
Polymer

7.200 g
[Total Polymer]

0.600 g

PVOH matrix

0.578 g

F-MMT stock

22.222 g

90.0%

1.93%

[F108]

0.022 g

[Dry MMT solids]

0.067 g

10.0%

30.000 g

100.0%

Total:
Note: [] are not added to the blend
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2.00%

0.07%

2.00%
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